Abstract: Thymidine phosphorylase (TP), also known as “platelet-derived endothelial cell growth factor” (PD-ECGF), is an enzyme, which is upregulated in a wide variety of solid tumors including breast and colorectal cancers. TP promotes tumor growth and metastasis by preventing apoptosis and inducing angiogenesis. Elevated levels of TP are associated with tumor aggressiveness and poor prognosis. Therefore, TP inhibitors are synthesized in an attempt to prevent tumor angiogenesis and metastasis. TP is also indispensable for the activation of the extensively used 5-fluorouracil prodrug capecitabine, which is clinically used for the treatment of colon and breast cancer. Clinical trials that combine capecitabine with TP-inducing therapies (such as taxanes or radiotherapy) suggest that increasing TP expression is an adequate strategy to enhance the antitumoral efficacy of capecitabine. Thus, TP plays a dual role in cancer development and therapy: on the one hand, TP inhibitors can abrogate the tumorigenic and metastatic properties of TP; on the other, TP activity is necessary for the activation of several chemotherapeutic drugs. This duality illustrates the complexity of the role of TP in tumor progression and in the clinical response to fluoropyrimidine-based chemotherapy.

Key words: thymidine phosphorylase (TP); angiogenesis; cancer chemotherapy; fluoropyrimidines; thymidine phosphorylase inhibitors
1. INTRODUCTION

Thymidine phosphorylase (TP) was first discovered in 1954 as a key enzyme of the pyrimidine salvage pathway, which recovers pyrimidine nucleosides that are formed during RNA or DNA degradation. TP catalyzes the conversion of thymidine and 2′-deoxyuridine to their respective bases and 2-α-D-deoxyribose-1-phosphate (2DDR-1P) (Fig. 1). This reaction is reversible; however, the most important metabolic function of TP is catabolic. TP also has deoxyribosyl transferase activity by which the deoxyribosyl moiety is transferred from a pyrimidine nucleoside to another pyrimidine base, resulting in the formation of a new pyrimidine nucleoside. Besides natural 2′-deoxynucleosides, TP also recognizes several pyrimidines or pyrimidine nucleosides with antiviral and antitumoral activity, such as 5-(E)-(2-bromovinyl)-2′-deoxyuridine (BVDU), 5-trifluorothymidine (TFT), 5-fluorouracil (5FU), and 5-fluoro-5′-deoxyuridine (5′DFUR), an intermediate metabolite of capecitabine, which is clinically used against metastatic breast and colon cancer (see Section 7.C).

In 1987, a so-called “new” protein was isolated from human blood platelets. This protein was believed to stimulate endothelial cell growth because it increased the [3H]-thymidine uptake and was therefore named “platelet-derived endothelial cell growth factor (PD-ECGF).” PD-ECGF was also shown to induce endothelial cell migration in vitro and angiogenesis in vivo and in the chicken “chorio-allantoic membrane (CAM)” assay. A few years later, it was reported that recombinant PD-ECGF has TP activity. Moreover, analysis of the amino acid sequence of both proteins revealed that PD-ECGF and TP are

![Figure 1](image-url)

**Figure 1.** Enzymatic reactions catalyzed by TP. TP catalyzes the reversible conversion of thymidine to thymine and 2DDR-1P. TP also has deoxyribosyl transferase activity by which the deoxyribosyl moiety is transferred from one pyrimidine base to another, resulting in the formation of a new nucleoside.
This leads to the conclusion that the observed increased thymidine uptake was an artifact, caused by the TP activity of PD-ECGF. TP in cell supernatant hydrolyzes serum-derived thymidine, depleting the cells of this metabolite. When the cells are subsequently incubated with [3H]-thymidine, the cells treated with TP take up more of the radiolabelled thymidine than the control cells. Thus, TP is not a growth factor.

A third role for TP has also been described and in this context TP is called gliostatin. In 1992, gliostatin was extracted from human neurofibroma. This protein inhibits the growth of both astrocytes and glial tumor cells. Gliostatin is also shown to promote the survival and neurite outgrowth of rat cortical neurons.

Thus, TP, PD-ECGF, and gliostatin are all synonyms that refer to the same, identical protein. Throughout the literature TP and PD-ECGF are used interchangeably, while the use of the word “gliostatin” is restricted to the context of rheumatoid arthritis (RA) and neurological research.

2. STRUCTURE OF TP

In the mid-1970s TP was purified from both Escherichia coli and Salmonella typhimurium. Several years later, human TP was extracted from the amniochorion. The amino acid sequence of TP is highly conserved during evolution. For example, human TP shares 39% sequence identity with E. coli TP.

TP functions as a homodimer consisting of two identical subunits (Fig. 2), with a dimer molecular mass ranging from 90 kDa in E. coli to 110 kDa in mammals. Detailed structural information on TP was first provided in 1990 by Walter et al. who solved the crystal structure of E. coli TP. This analysis revealed that each subunit contains a large mixed α-helical and β-sheet domain (α/β domain) separated from a smaller α-helical domain (α-domain) by a large cleft. The active site consists of the thymine-binding site in the α-domain and the phosphate-binding site across the cleft in the α/β domain. The finding that both sites were about 8 Å apart immediately suggested that a hinge motion of one domain relative to the other was necessary to generate a closed conformation of the enzyme containing a catalytically competent active site, as that seen in the crystal structure of the related pyrimidine nucleoside phosphorylase from Bacillus stearothermophilus. This closing/opening motion in the presence of substrate, product, and transition state has been simulated using steered molecular dynamics.

It took several more years to have the structure of human TP solved because many crystallization trials failed to produce well-diffracting crystals. Thus, Spraggon et al. reported crystals of human TP for which, despite using a synchrotron X-ray source, diffraction was limited to 3.5 Å resolution. Finally, in 2004, Norman et al. successfully solved at 2.1 Å resolution the structure of human TP in complex with the small and potent inhibitor 5-chloro-6-[1-(2-iminopyrrolidinyl)methyl] uracil (TPI) (see Section 6.A). Nonetheless, limited proteolysis with trypsin was found to be necessary and this treatment yielded a structure in which amino acids 409 and 410 were missing and the loop formed by amino acid residues 405–416 was disordered. In these crystals, TP was found as a dimer, with each monomer in the closed, active conformation, and TPI mimicking the substrate transition state. This work provided the first structural insight into the binding mode of an inhibitor to a pyrimidine nucleoside phosphorylase.

In 2006, El Omari et al. managed to determine the structure of unproteolyzed human TP at 2.3 Å resolution with the aid of the small-molecule inhibitor KIN59 (see Section 6.B), which helped to obtain good quality diffracting crystals although it could not be located in the electron density map. The asymmetric unit revealed two dimers each displaying the same inter-subunit contacts that were observed in the previous structure and, in

Medicinal Research Reviews DOI 10.1002/med
addition, a fully visible loop made up of residues 405–416. In Figure 2, a ribbon representation of human TP is shown, clarifying the dimeric structure and a detail of the active site containing either the inhibitor TPI or the thymine product (C atoms in white). The dimer interface consists of a coiled coil formed by helices from each closed-conformation monomer. Superimposition of both available X-ray structures highlights their overall similarity despite belonging to different space groups. The side chains of active-site residues His116, Leu148, Tyr199, Arg202, Ser217, and Lys221 are displayed as sticks.

Figure 2. Ribbon representation of human TP showing the dimeric structure and a detail of the active site (boxed) containing either the TPI inhibitor (C atoms in orange) or the thymine product (C atoms in white). The dimer interface consists of a coiled coil formed by helices from each closed-conformation monomer. Superimposition of both available X-ray structures highlights their overall similarity despite belonging to different space groups. The side chains of active-site residues His116, Leu148, Tyr199, Arg202, Ser217, and Lys221 are displayed as sticks.

addition, a fully visible loop made up of residues 405–416. In Figure 2, a ribbon representation of human TP is shown, clarifying the dimeric structure and a detail of the active site containing either the inhibitor TPI or the thymine product. Strikingly, the product thymine was present in three of the four monomers of the asymmetric unit rather than the substrate thymidine, which had been added at the start of the crystallizations. As kinetic studies of E. coli TP have shown that phosphate is the first substrate that binds to TP whereas 2DDR-1P dissociates last from the enzyme, this finding suggests that after product release, thymine is able to reassociate with the unliganded enzyme and stabilize the closed conformation, which may explain the mechanism of noncompetitive product inhibition.
3. EXPRESSION OF TP IN HEALTH AND DISEASE

A. The Physiological Role of TP

TP is found in many normal tissues and cells, with high levels in macrophages, stromal cells, glial cells, reticulocytes, some epithelia, tissues of the digestive tract (oesophagus and the rectum), salivary gland, brain, bladder, spleen, lymph, and the lungs.\textsuperscript{28–30} Within the cell, TP is present in both the cytoplasm and the nucleus.\textsuperscript{28}

Blood platelets are one of the richest sources of TP, which suggests a role for the enzyme in wound healing. TP activity is also detected in plasma and serum, where its presence is probably due to blood platelet damage or cell turnover.\textsuperscript{31}

Furthermore, TP plays an important role in the female reproductive cycle. Large quantities of TP are found in the placenta, where two alternative forms of the protein are detected. One is a 27 kDa splice variant of TP,\textsuperscript{32} while the other form contains five additional amino acids on the N-terminus and is processed at Thr-6 instead of Ala-11.\textsuperscript{33} Whether these structural differences also result in functional differences is not clear. High amounts of TP were also discovered in the endometrium, which undergoes extensive angiogenesis during each menstrual cycle. TP shows a characteristic pattern of distribution dependent on the phase of the menstrual cycle: TP expression moves from stroma to epithelium as the cycle progresses\textsuperscript{34} and is inversely correlated with oestradiol concentrations.\textsuperscript{35} Endometrial TP expression was also raised by human chorionic gonadotropin\textsuperscript{36} and by a combination of progesterone and transforming growth factor \(\beta1\).\textsuperscript{34} A marked increase of TP was also detected in decidualized endometrium.\textsuperscript{37} During the first trimester of pregnancy, TP is found in the trophoblast together with vascular endothelial growth factor (VEGF), which indicates that both factors play an active role during gestation.\textsuperscript{32}

B. TP in Inflammatory Diseases

Various studies indicate that TP is also involved in a wide variety of chronic inflammatory diseases (see Table I). This may be explained by the fact that (i) inflammatory cells such as macrophages contain large amounts of TP (cf. Section 3.D) and (ii) inflammatory cytokines (such as interleukin-1 and tumor-necrosis factor-\(\alpha\)) induce TP expression (see Section 5).

TP levels are raised in psoriasis.\textsuperscript{38,39} Accordingly, a 20-fold increase in TP activity was found in psoriatic lesions.\textsuperscript{39} In inflammatory bowel disease, strong TP expression was observed, predominantly in macrophages and fibroblasts of the inflamed colonic mucosa and the grade of expression augmented with an increasing grade of inflammation.\textsuperscript{40,41} In addition, TP was found in the endothelial cells of the inflamed colonic mucosa.\textsuperscript{40,41} Furthermore, TP is upregulated in chronic glomerulonephritis (a renal disease characterized by inflammation of the glomeruli) where it probably plays a critical role in the progression of interstitial fibrosis.\textsuperscript{42} Moreover, TP is expressed in atherosclerosis. Macrophages, foam cells, and giant cells from both aortic and coronary plaques were found to be immunoreactive for this angiogenic factor, suggesting that TP may play a role in the pathogenesis of atherosclerosis.\textsuperscript{43}

TP is also implicated in RA. Higher levels of TP were found in the synovial fluid or sera of patients with RA than in patients with osteoarthritis or normal healthy individuals and serum TP was found to be a useful clinical marker for RA.\textsuperscript{44–46} Furthermore, the intra-articular injection of recombinant TP into the knees of rabbits induced RA-like synovitis.\textsuperscript{47} Both wild-type TP or mutant (K115E) TP, which lacks enzymatic activity, caused this effect, indicating that not the enzymatic activity of TP but rather the protein itself is implicated in the pathology of RA.\textsuperscript{47} Further studies revealed that TP augments its own synthesis through an autocrine mechanism in fibroblast-like synoviocytes (FLS).\textsuperscript{48} TP also induced the extracellular secretion of matrix metalloproteinase-1 (MMP-1) and MMP-3, which are the major
triggers of cartilage degeneration.\textsuperscript{48,49} TP was also found to upregulate both mRNA and protein levels of VEGF, suggesting that both factors have synergistic effects on angiogenesis in RA.\textsuperscript{50}

C. The Involvement of TP in MNGIE

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive human disorder associated with multiple deletions of skeletal muscle mitochondrial DNA.\textsuperscript{51} This disease is characterized clinically by ptosis, progressive external ophthalmoplegia, gastrointestinal dysmotility, thin body habitus, peripheral neuropathy, myopathy, leukoencephalopathy, and lactic acidosis. Loss-of-function mutations of the TP gene were identified as the possible cause of this disease.\textsuperscript{52,53} In MNGIE, the severely reduced TP enzyme activity leads to an increase in the plasma and tissue thymidine and 2'-deoxyuridine levels.\textsuperscript{53–55} This may cause unbalanced mitochondrial nucleoside and nucleotide pools, which lead to impaired mitochondrial DNA replication and repair. Therefore, therapies that decrease thymidine levels may be beneficial to MNGIE patients.\textsuperscript{53}

In order to unravel the role of TP in MNGIE, mice deficient in the TP gene were generated. As mouse uridine phosphorylase (UP) may also cleave thymidine, TP\textsuperscript{−/−}UP\textsuperscript{−/−} double knockout mice were constructed. In these TP\textsuperscript{−/−}UP\textsuperscript{−/−} mice, all TP activity was abrogated and the plasma thymidine levels were 5-fold higher than in wild-type mice. Surprisingly, no alterations in mtDNA or pathological changes in the muscles of these knockout mice could be observed.\textsuperscript{56,57} Only in the brain, mitochondrial DNA depletion, respiratory chain defects and histological alterations could be detected.\textsuperscript{57} The brain-specific phenotype in TP\textsuperscript{−/−}UP\textsuperscript{−/−} mice may be due to the relatively modest increases in thymidine or 2'-deoxyuridine levels in mutant mice (5-fold increase in mice versus 100-fold increase in humans). Another possible explanation is the shorter lifespan of mice compared to humans because in humans the average age-at-onset of symptoms of MNGIE is 18.7 years.\textsuperscript{58}

Nevertheless, other studies suggest that functional mutations of the TP gene are not sufficient to induce MNGIE. Kumagai et al. postulated that TP gene mutation is not the primary cause of this mitochondrial disease because TP mutations are also found in unrelated healthy individuals.\textsuperscript{59} Examination of chromosome 22q13.32 where the TP gene is located, revealed that exon 10 of TP overlaps with the SCO2 gene,\textsuperscript{56} which is a cytochrome c oxidase (COX) assembly gene.\textsuperscript{60} Mutations in SCO2 have been reported to cause severe COX

\begin{table}[h]
\centering
\caption{Biological Functions of TP}
\begin{tabular}{ll}
\hline
\textbf{Physiological role} & References \\
Salvage of pyrimidines & 1 \\
Female reproductive cycle & 32–37 \\
Wound healing & 31 \\
\hline
\textbf{Pathological role} & \\
Cancer & 63–205 \\
Inflammatory diseases & \\
Reumatoid arthritis & 44–50 \\
Atherosclerosis & 43 \\
Psoriasis & 38, 39 \\
Inflammatory bowel disease & 40, 41 \\
Chronic glomerulonephritis & 42 \\
MNGIE & 51–58 \\
\hline
\end{tabular}
\end{table}
deficiency in skeletal muscle leading to mitochondrial disorders characterized by hypertrophic cardiomyopathy and encephalopathy. Thus, more investigations are needed to clarify the exact role of TP deficiency in MNGIE development.

So far no vascular abnormalities have been reported in MNGIE patients nor in TP−/− UP−/− mice. These data suggest that TP is not of fundamental importance for developmental angiogenesis.

**Figure 3.** Correlation of TP expression in various cancers with the clinicopathological factors microvessel density, tumor stage, and grade.

*Medicinal Research Reviews* DOI 10.1002/med
D. TP Overexpression in Cancer

Increased TP expression in tumor tissues compared to corresponding nonneoplastic tissue was found in breast,63 bladder,64,65 gastric,29,66,67 colorectal,29,68 lung,68,69 esophageal,68,70 and cervical68,71 cancers but not in cancers of the liver,68,72 common bile duct,68 and the thyroid.68 TP expression is not only upregulated in solid tumors, elevated levels of TP were also observed in lymph nodes of patients with classical Hodgkin lymphoma where TP levels increased with disease progression.73 Recently, tumor-reactive T cells from a patient with relapsed multiple myeloma (who was successfully treated with donor lymphocyte infusion after allogeneic stem cell transplantation) were found to be directed against TP.74 These data identify TP as a potential target for the immunotherapy of hematological tumors.

Numerous studies on cancer patients have examined the relation between TP expression and microvessel density, tumor grade, stage, metastasis, and prognosis. In these studies TP was measured by RT-PCR, immunohistochemistry, or by activity assays. The results of these reports are summarized in Figures 3 and 4.64–67,70,71,75–205 These figures include only the cancer types for which the association between TP and the respective tumor-related parameter has been investigated in more than three independent studies. Generally, TP expression is correlated with higher microvessel density, higher tumor stage, and more metastasis. An
association of TP with tumor grade is evident in bladder, cervical, and renal cell cancer, but not in the other investigated cancers. Furthermore, in most cases, TP appeared to be associated with poor prognosis, although there are conflicting reports for some cancers. For example, seven of the nine studies on colon cancer reported a significant correlation between TP and bad prognosis, while Saito et al. demonstrated that TP is associated with good prognosis. These discrepancies might be caused by differences in the histological type of cancer, stage (early versus advanced stage of disease), number of patients examined, assay for TP and different methodology for the evaluation of the immunohistochemistry results.

Tumors are heterogeneous tissues consisting of unknown variable contributions of tumor, stromal, and infiltrating cells. Besides tumor cells, also endothelial cells, fibroblasts, lymphocytes and especially tumor-associated macrophages (TAM) express TP. TAM are thought to play a key role in stimulating tumor growth and metastasis through the production of various growth factors, proteinases, chemokines, and cytokines. High levels of TP have been demonstrated in TAM of melanoma, gastric, glioblastoma, breast, colon, astrocytic, uterine endometrial, and prostate cancer. In gastric adenocarcinoma, astrocytic tumors, breast, and uterine endometrial cancer, TP expressed in macrophages has been suggested to be correlated with microvessel density and to play an important role in tumor invasiveness.

Elevated TP levels are not only found in the tumor tissue but also in the plasma of cancer patients. Already in 1977, Pauly et al. demonstrated that cancer patients had much higher TP activity in the plasma than healthy individuals. He also reported that tumor-bearing animals have elevated TP activity in their ascites and plasma. More recent data indicate that plasma TP concentrations in cancer patients may have a prognostic value. In uterine cervical cancer high serum TP levels correlate with clinical stage, tumor size, lymph node metastasis, and an extremely poor prognosis. High TP concentrations in the blood are also associated with depth of tumor invasion and poor response to treatment in patients with esophageal squamous cell carcinoma. Furthermore, in patients with colorectal cancers, the TP serum level is suggested to be a novel marker to predict occurrence of hematogenous metastasis.

4. TP AND TUMOR DEVELOPMENT

A. Role of TP in Angiogenesis (Fig. 5)

Angiogenesis, the formation of new capillaries from existing blood vessels, is of fundamental importance in several physiological processes, such as embryonic development, wound repair, and reproduction (see Table II). It is a multistep process that involves degradation of the surrounding extracellular matrix (ECM) by proteases, endothelial cell migration, proliferation, and differentiation into mature blood vessels. Cytokines, growth factors, growth factor receptors, enzymes (like TP), components of the ECM, and adhesion molecules each have their own specific role in this well-coordinated process. The equilibrium between angiogenic and angiostatic proteins, the so-called angiogenic balance, in the microenvironment controls the rate of new blood vessel formation. Alteration of this angiogenic balance, for example by the uncontrolled release of angiogenic regulators, can lead to several pathological conditions including inflammation, RA, tumor growth, and metastasis.

TP induces endothelial cell migration and tube formation in vitro. This enzyme was also shown to stimulate angiogenesis in the CAM and in several in vivo models, such as the freeze-injured skin graft, rat corneal, and mouse dorsal air sac assays and in gelatine
sponges subcutaneously implanted in rats or mice. Recently, proteomic research has identified TP as a key regulator of the angiogenic potential of endothelial progenitor cells (EPC). EPC are bone marrow-derived cells, which can differentiate into endothelial cells and

Table II. Molecular Mediators of TP and/or 2DDR in Angiogenesis

| Molecular mediators | Cell type | References |
|---------------------|-----------|------------|
| MMP-1               | Human bladder RT-112 cells | 48, 234 |
| MMP-2               | RA-associated synoviocytes | 256 |
| MMP-3               | Cervical carcinoma cells | 48 |
| MMP-7               | Human PC-3 prostate cancer cells | 258 |
| MMP-9               | Human PC-3 prostate cancer cells | 257, 258 |
| VEGF                | Human bladder RT-112 cells | 234 |
| Integrins α₅β₁ and αᵥβ₃ | HUVEC | 225, 240 |
| IL-8                | Human bladder RT-112 cells | 234 |
| P-selectin          | HUVEC | 260 |

Figure 5. The role of TP in tumor progression. TP expression in tumors can be upregulated by various stress-inducible factors, such as radio- and chemotherapy, inflammatory cytokines, hypoxia, and low pH. Within the tumor tissue, TP is found in both tumor-associated macrophages and tumor cells. TP and its metabolite 2DDR stimulate tumor growth by promoting angiogenesis. TP and 2DDR stimulate the secretion and/or expression of the angiogenic molecules VEGF, IL-8, P-selectin, and various MMPs. 2DDR, which can diffuse outside of the cell, also directly induces endothelial cell migration through activation of the integrins α₅β₁ and αᵥβ₃. TP and 2DDR may also induce tumor progression by protecting the tumor against apoptosis induced by hypoxia, Fas, DNA-damage, and microtubuli-interfering agents. Conversely, tumors do not always profit from elevated TP levels as TP plays a crucial role in the activation of chemotherapeutic drugs such as capecitabine. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
contribute to the repair of blood vessels after a myocardial attack. These cells thus offer a promising strategy for the treatment of various cardiovascular diseases. Furthermore, because these cells have the capacity to home to, and invade, tumor tissues, they also show potential as a target for gene therapy against malignant tumors.

Numerous experimental data indicate that the catalytic activity of TP is indispensable for its angiogenic properties: (i) unlike wild-type TP, TP mutants that lack enzymatic activity did not induce the formation of new blood vessels in the gelatine sponge assay; (ii) the angiogenic activities of TP could be abolished by using TP-directed neutralizing antibodies; by addition of a specific TP inhibitor such as 5-amino-6-chlorouracil or by downregulating TP by siRNA; and (iii) 2-deoxy-D-ribose (2DDR), which is a degradation product of the TP-metabolite 2DDR-1P, also induces endothelial cell migration and angiogenesis. Besides 2DDR, other metabolites of TP have been shown to possess angiogenic properties in vitro. β-amino-isobutyric acid, which is a degradation product of thymine, stimulated tube formation in the rat aortic assay, while 2DDR-1P induced endothelial cell migration. Nevertheless, 2DDR is considered to be responsible for the angiogenic activities of TP. de Bruin et al. showed that 2DDR-1P produced by TP-overexpressing Colo320 colon carcinoma cells is rapidly converted to 2DDR. Therefore, it can not be excluded that the biological activity obtained for 2DDR-1P is a result of the conversion of 2DDR-1P to 2DDR. Moreover, Hotchkiss et al. showed that the conversion of 2DDR-1P to 2DDR is indispensable for the induction of endothelial cell migration as addition of an alkaline phosphatase inhibitor, which blocks the dephosphorylation of 2DDR-1P, completely abrogated the chemotactic effects of 2DDR-1P. Moreover, a neutralizing antibody to TP had no effect on endothelial cell migration stimulated by TP-overexpressing cells, even though this antibody completely inhibited migration mediated by recombinant, extracellular TP. These studies demonstrate that TP-mediated endothelial cell migration relies on the intracellular catabolism of thymidine and subsequent extracellular release of 2DDR, which forms a chemotactic gradient. In spite of this, the enzyme purine nucleoside phosphorylase, which also produces 2DDR, has never been reported to possess angiogenic properties.

In several ways, TP is a very exceptional angiogenic molecule. Indeed, usually, angiogenic factors are released into the extracellular space to activate endothelial cells. However, TP lacks an amino-terminal hydrophobic leader sequence required for cell secretion and is therefore mainly found inside the cell. Nevertheless, some tumor cell lines such as the epidermoid carcinoma A431 and stomach cancer MKN74 cell lines do release the protein into the cell culture medium. Also cytokine-treated FLS have been shown to actively secrete TP. The mechanism behind the secretion of TP is possibly a posttranslational process whereby serine residues of TP are covalently linked to phosphate groups of nucleotides, leading to the formation of a nucleotidylated protein that can be secreted. While TP mostly remains inside the cell, its metabolite 2DDR is able to cross the cell membrane and exert its biological effects on other cells. Furthermore, angiogenic factors usually bind to a specific cell surface receptor, which induces a signal transduction cascade followed by a biological response of the cell. However, mammalian cells do not seem to have a receptor for TP nor for 2DDR. Several bacterial receptors for carbohydrates, including for D-ribose, have been identified that play a role in chemotaxis. These receptors are histidine kinases, which is a family of receptors that is found in prokaryotes and eukaryotes but not in the animal kingdom. Thus, TP and 2DDR most likely induce angiogenesis through a non-receptor-mediated mechanism.

1. TP stimulates endothelial cell migration

The molecular mechanisms through which TP and 2DDR stimulate endothelial cell migration in vitro are not completely understood. Hotchkiss et al. revealed that TP and 2DDR affect
endothelial cell migration through activation of integrins and their downstream signalling pathways. In human umbilical vein endothelial cells (HUVEC), it was shown that both TP and 2DDR stimulate the formation of focal adhesions and the phosphorylation of tyrosine 397 of focal adhesion kinase (FAK). FAK is a nonreceptor protein–tyrosine kinase that is recruited to focal adhesions by integrin engagement with the ECM. Thus, FAK plays an important role in endothelial cell attachment and migration. Hotchkiss et al. demonstrated that VEGF, TP, and 2DDR all stimulate HUVEC migration, although through different integrins. TP- and 2DDR-mediated endothelial cell migration and FAK phosphorylation were blocked by antibodies against either integrin α5β1 or αvβ3, whereas VEGF-induced migration was only inhibited by the α5β3 antibody. The cell surface expression of integrin α5β1 and the cellular expression of integrin β3 were increased by TP and 2DDR.

Also other investigators tried to unravel the signalling pathways through which 2DDR activates endothelial cells. Seeliger et al. demonstrated that rapamycin completely abrogates 2DDR-mediated HUVEC migration and tube formation in the rat aortic ring assay, probably by blocking 2DDR-induced p70/s6 kinase activation. The intracellular p70/s6 kinase is known to induce endothelial cell migration after activation of the mammalian target of rapamycin. It has been shown that p70/s6 kinase activation is induced after interaction of integrins with ECM components and that this activation requires FAK.

2. TP induces the expression and/or secretion of other angiogenic factors

Various studies have demonstrated that TP and 2DDR promote the expression and secretion of several angiogenic factors (see Table II). Human bladder carcinoma cells transfected with TP (RT112-TP) secrete higher amounts of VEGF, interleukin-8, and MMP-1 than mock-transfected RT112 cells in the presence of thymidine. RT112-TP cells incubated with thymidine also showed an elevated expression of heme oxygenase-1 (HO-1). HO-1 is an enzyme that catalyzes the degradation of heme to carbon monoxide, iron, and biliverdin. The expression of HO-1 can be induced by hypoxia, cytokines, and several angiogenic factors such as VEGF and stromal cell derived factor-1 (SDF-1). Recent data indicate that HO-1 also possesses proangiogenic properties: it promotes endothelial cell proliferation, protects endothelial cells from apoptosis, and induces the secretion of several angiogenic mediators such as VEGF. Among the different end products of the enzyme reaction of HO-1, carbon monoxide is proposed to be responsible for the angiogenic actions of HO-1, although recently also biliverdin has been reported to stimulate the synthesis of angiogenic mediators. Not only in RT112-TP cells an elevated expression of HO-1 occurred, also in TP-overexpressing vascular smooth muscle cells (VSMC) an induction of HO-1 was observed. An excess of thymine, which acts as a scavenger for the formed 2DDR-1P, prevented the induction of HO-1. Brown et al. suggested that 2DDR is a strongly reducing sugar that may generate oxygen radical species during the early stages of protein glycation. It was hypothesized that 2DDR binds to an amino group (preferentially at a lysine, arginine or the N-terminal amino acid) of a protein during a nonenzymatic reaction, the so-called Maillard reaction. This may lead to the formation of a Schiff base, which can then rearrange to an α-hydroxyketone. This unstable reaction intermediate autoxidizes during which reaction free oxygen radicals are produced. Thus, through the formation of 2DDR, TP may induce oxidative stress in TP-overexpressing tumor cells causing these cells to secrete angiogenic factors, such as VEGF. A recent study demonstrates that TP may induce VEGF secretion through another mechanism. Transcription of VEGF is known to be driven by hypoxia-inducible factor-1α (HIF-1α). Under hypoxic conditions, the transcription factor HIF-1α is upregulated and increases the expression of several target genes by forming a dimer with HIF-1β, which recognizes the hypoxia responsive elements in the promoter.
In RT112 cells, TP activity augments the levels of HIF-1α during in vitro hypoxia and TP and HIF-1α acted together to induce VEGF secretion. Not only MMP-1, but also other MMPs have been shown to be upregulated by TP. MMPs degrade the ECM surrounding tumor and endothelial cells and therefore promote tumor cell invasion, migration, and metastasis. In several cervical carcinoma cell lines, TP expression correlated significantly with the mRNA level of MMP-2 and with cell invasion in vitro. Human epidermoid carcinoma cells (KB) transfected with TP expressed more MMP-9 while the TP-overexpressing PC-3 prostate and KK47 bladder cancer cells had higher levels of MMP-7 and MMP-9 under hypoxia than the mock-transfected control cells. TP induced the expression and extracellular secretion of MMP-1 and MMP-3 in cultured human RA-associated synoviocytes. Also clinical data provide evidence for a correlation between TP and MMP expression. In breast cancer, TP was associated with higher levels of activated MMP-9. Moreover, in human bladder cancers, TP correlated significantly with the expression of MMP-1, MMP-9, and urokinase plasminogen activator, which also plays a role in ECM degradation.

cDNA microarray analysis showed that the cell adhesion molecule P-selectin is upregulated in HUVEC treated with TP. A correlation between tumor cell P-selectin expression and TP was also assessed in human breast cancers by immunohistochemistry. P-selectin is a vascular adhesion molecule mostly found on endothelial cells that mediates the interactions of endothelial cells and leukocytes during inflammation. It is also believed to play a vital role in tumor growth and metastasis, including the promotion of angiogenesis and the movement of tumor cells through the endothelial cell layer.

A study on breast cancers revealed that angiopoietin-1 (Ang-1) is inversely related to TP. Ang-1, which is a ligand of the tyrosine kinase receptor Tie-2, is a survival factor for endothelium and stabilizes vascular networks. It maintains the integrity of the capillaries by recruiting and stabilizing nonendothelial support cells such as pericytes. Thus, the loss of Ang-1 results in pericyte–endothelial cell contact destabilization, which possibly enables TP and 2DDR to act on the “free” endothelial cells and induce angiogenesis.

3. TP is a promising target for the treatment of vascular obstructive diseases

As TP is an angiogenic molecule, its upregulation could be applied to treat diseases caused by reduced angiogenesis or a disturbed blood flow. In 2005, Li et al. showed that gene therapy using TP is an effective treatment against chronic myocardial ischemia in dogs. The plasmid-mediated gene transfer of TP stimulated angiogenesis and arteriogenesis in chronically ischemic myocardium, decreased the infarct size, restored the myocardial blood flow, and improved myocardial function. This experimental gene therapy also proved to have a long-term beneficial effect in the treatment of chronic ischemic myocardium.

As VSMC play an important role in vessel maturation during angiogenesis, and deregulated growth or motility of VSMC contributes to the pathogenesis of vascular obstructive diseases (such as ischemia), the effect of TP on VSMC migration and proliferation was investigated. TP-overexpressing VSMC migrated and proliferated more slowly than mock-transfected VSMC. The decreased VSMC proliferation was correlated with TP-induced HO-1 expression. In TP-overexpressing VSMC the cyclin-dependent kinase inhibitor (p27KIP1) was upregulated and the cell cycle was arrested at the G1 phase. Thus, surprisingly, TP inhibits proliferation and migration of VSMC, while it stimulates the migration of endothelial cells. This apparently conflicting role of TP may be due to the opposite effect of HO-1 in endothelial cells and VSMC. As described above, TP induces HO-1 both in endothelial cells and VSMC. HO-1 has been shown to induce endothelial cell proliferation and migration, while it inhibits VSMC growth. In balloon-injured rat carotid arteries adventitial TP gene delivery significantly reduced neointimal VSMC migration and neointima.
formation. Furthermore, adventitial delivery of the TP gene also prevented intimal hyperplasia of vein grafts in rabbits. TP thus reduces the neointimal mass and inhibits further neointimal outgrowth and is therefore a promising target in occlusive vascular diseases.

B. TP Induces Metastasis

TP was found to increase the metastatic potential of several experimental and human tumors. Moreover, in various cancers high TP expression correlates with metastasis (Fig. 4). Takao et al. demonstrated that TP-expressing KB carcinoma cells show more basement membrane invasion than their mock-transfected counterparts. Intrasplenic injection of KB/TP cells in nude mice resulted 4 weeks after injection in significantly more metastatic nodules in the livers than injection with KB/CV cells. The stimulation of metastasis by TP-overexpressing cells could be dramatically inhibited by the TP inhibitor TPI or by 2-deoxy-L-ribose (2DLR), a stereoisomer of 2DDR. Finally, in mice xenografted with the human melanoma cancer cell line A-07, lung colonization and spontaneous metastasis were inhibited by treatment with neutralizing antibodies against TP.

C. TP Protects Cancer Cells Against Apoptosis

Moghaddam et al. reported in 1995 that TP-expressing breast carcinomas have a higher growth rate without an increase in microvessel density than breast cancers that do not express TP. Furthermore, a clinical study of human colon carcinomas showed that TP is a prognostic factor independent of angiogenesis. These data suggest that TP may stimulate tumor growth through a mechanism different than angiogenesis. Uchimiya et al. investigated in a mouse model the anti-apoptotic effect of TP by injecting KB/TP cells or mock-transfected KB cells (KB/CV) into nude mice. The apoptotic index in KB/TP tumors was significantly lower than in KB/CV tumors, indicating that TP protects cells against apoptosis. Also numerous clinical studies give evidence for the anti-apoptotic effect of TP. TP expression is correlated with a reduction in apoptotic cells in colon, gastric, esophageal, ovarian, and oral squamous cell carcinomas but not in cervical cancers or in astrocytic tumors.

A correlation between TP expression and apoptosis was first demonstrated in vitro by using human epidermoid carcinoma KB cells. KB cells transfected with TP (KB/TP) were resistant to hypoxia-induced apoptosis. This advantage was abrogated when the cells were treated with TPI, which inhibits the enzymatic activity of TP, leading to the conclusion that the enzymatic activity of TP is indispensable for protection against hypoxia-induced apoptosis. Also the metabolites of the TP reaction, 2DDR, and thymine, partially prevented hypoxia-induced apoptosis in KB cells. A potential molecular basis for the inhibition of hypoxia-induced apoptosis was first suggested by Ikeda et al. In human leukemia (HL-60) cells, 2DDR inhibited numerous hypoxia-induced pro-apoptotic events, such as activation of caspase 3 and 9, mitochondrial cytochrome c release, loss of mitochondrial transmembrane potential, phosphorylation of p38 mitogen-activated protein kinase, and downregulation of the anti-apoptotic proteins Bcl-2 and Bcl-xl. Furthermore, 2DDR also prevented the upregulation of the transcription factor HIF-1α. Also in the human leukemia cell line (Jurkat cells) overexpression of TP inhibited the upregulation of HIF-1α and the HIF-1α-inducible, pro-apoptotic factor BNIP3. This is in contradiction with the results of Brown et al. who showed that TP-activity augments the levels of HIF-1α in RT-112 cells during in vitro hypoxia. It is however possible that different tumor cell lines demonstrate considerable variation in induction of HIF-1α when subjected to TP. Another explanation might be that in HL-60 cells, 2DDR was added extracellularly, while in RT-112 cells the effect was observed in cells transfected with TP.
Besides hypoxia-induced apoptosis, TP suppresses apoptosis induced by Fas, microtubule-interfering, and DNA damage-inducing agents such as cisplatin (see Table III).\textsuperscript{282–286} TP exerts these protective effects independent of its enzymatic activity.\textsuperscript{282,283,286} Furthermore, in the presence of UV-light, which causes DNA damage, KB/TP cells had higher amounts of both Akt and phosphorylated Akt than KB/CV cells. Akt activation was significantly decreased by phosphatidylinositol 3 kinase (PI3K) inhibitors, suggesting that the Akt/PI3K pathway is implicated in TP-induced resistance against DNA damage.\textsuperscript{284} Finally, it was demonstrated that TP protects cells against Fas-induced apoptosis by inhibiting caspase-8 cleavage, Bcl-2 phosphorylation, and cytochrome c release.\textsuperscript{285}

5. REGULATION OF TP EXPRESSION

The TP gene is localized on chromosome 22q13\textsuperscript{287} and is composed of ten exons dispersed over a 4.3 kb region. The TP promoter lacks a "TATA" and a "CCAAT" box, sequences recognized by RNA polymerase II, prevalent in most eukaryotic genes.\textsuperscript{288} Instead, it contains a cluster of six to nine SP1-binding motifs, just upstream of the transcription start site.\textsuperscript{288,289} The transcription factor SP1 is activated by protein kinase A, which is in turn activated by cyclic adenosine monophosphate (cAMP).\textsuperscript{290} SP1 sites are also involved in the transcription of VEGF.\textsuperscript{291} Indeed, various studies confer the tendency for VEGF and TP to be co-expressed. A significant correlation was found between expression of VEGF and TP in breast,\textsuperscript{118,124,292} colorectal,\textsuperscript{293} non-small cell lung,\textsuperscript{69,133} head and neck squamous cell,\textsuperscript{294} endometrial,\textsuperscript{79} astrocytic,\textsuperscript{165} lung,\textsuperscript{295} and cervical\textsuperscript{296} carcinomas. The co-expression of TP and VEGF may also be explained by the fact that TP increases the expression of VEGF by inducing oxidative stress or by upregulating the transcription factor HIF-1α, as described in Section 4.A.2. However, no relation between VEGF and TP expression was found in gastric,\textsuperscript{80} gallbladder,\textsuperscript{297} bladder,\textsuperscript{298} and esophageal squamous cell\textsuperscript{191} carcinomas.

Besides SP1 sites, the promoter region of the TP gene contains other transcription factor-binding sites, such as an interferon-stimulated response element (ISRE)\textsuperscript{299} and a γ-activated sequence-like element (GAS).\textsuperscript{300} In HT29 colon carcinoma cells, interferon-γ (IFN-γ) induces TP expression through these ISRE sequences,\textsuperscript{299} while in U937 monocytes IFN-γ promotes TP expression by increasing the binding of the signal transducer and activator of transcription 1 (STAT1) to the GAS sequence, suggesting that IFN-γ induces TP expression by activation of the Janus kinase (JAK)/STAT pathway.\textsuperscript{300} This observation is in line with the findings of Yao et al. who reported that the JAK inhibitor AG-490 blocks both IFN-induced STAT1 phosphorylation and TP expression in glioblastoma cells.\textsuperscript{301} Furthermore, in clinically resected colon carcinomas eight of nine tumors tested had both high STAT1 protein levels and TP activity.\textsuperscript{302} The IFN-induced TP gene expression is also regulated by post-transcriptional mechanisms. Schwartz et al. demonstrated that IFN induces an increase in TP mRNA and that the TP mRNA levels remained elevated for up to 72 hr, suggesting that IFN promotes TP mRNA stability. Analysis of the TP mRNA sequence revealed the presence of a pyrimidine-rich sequence at the 3'-end that is similar to a motif that has been reported to increase the mRNA stability in other genes such as VEGF.\textsuperscript{299}

Interferons are not the only inflammatory cytokines that upregulate TP. Also tumor necrosis factor-α (TNF-α) and interleukins induce the expression of TP.\textsuperscript{46,289,303,304} In THP-1 monocytes TP expression was increased by TNF-α and this induction could be mimicked by an antibody against TNF-α receptor.\textsuperscript{2,303,304} It was also shown that the TNF-α-induced increase in TP mRNA was inhibited by an inhibitor of transcription factor nuclear factor-κB (NF-κB).\textsuperscript{304} Correspondingly, de Bruin et al. showed that prolonged exposure of human macrophage THP1 and U937 cells to sulfasalazine, an anti-inflammatory drug and inhibitor.

Medicinal Research Reviews DOI 10.1002/med
of NF-κB, resulted in downregulation of TP and IL-8 along with elimination of their induction by TNF-α and IFN-γ. Thus, the transcription factor NF-κB is involved in the induction of TP expression.

In cultured FLS, TNF-α, IL-1α, IL-1β, IL-6, and IL-8 stimulated the expression of TP. The IL-1β-induced expression of TP was inhibited by treatment with the anti-rheumatic drugs dexamethasone and aurothioglucose, while methotrexate or sulfasalazine had no influence on the TP levels. This suggests that dexamethasone and aurothioglucose may inhibit RA through inhibition of TP expression. Also in OUMS-27 chondrosarcoma cells the secretion of TP was augmented by IL-1β in a dose-dependent manner. This effect could be blocked by selective inhibition of the p38 mitogen-activated protein kinase (p38 MAPK) pathway.

Cancer treatments, such as X-ray irradiation and chemotherapeutic agents (including paclitaxel, docetaxel, doxorubicin, oxaliplatin, cyclophosphamide, and mitomycin C) have been reported to dramatically increase the tumor TP levels (see Table III). This is probably due to the fact that these therapies induce cytokines (such as TNF-α, IFN-γ, IL-1) that stimulate TP expression.

Recently, evidence was provided that TP expression is also regulated at the transcription level by epigenetic modifications, such as methylation and histone deacylation. High

### Table III. Molecular Mechanisms of the Anti-Apoptotic Effect of TP

| Apoptosis induced by | Involvement of catalytic activity of TP | Cell type | Anti-apoptotic actions of TP | Ref. |
|---------------------|----------------------------------------|-----------|-----------------------------|------|
| Hypoxia             | Yes                                    | KB epidermoid cells | Inhibition of Caspases 3 and 9 activation | 278  |
|                     |                                        |            | Cytochrome c release        |      |
|                     |                                        |            | p38 MAPK phosphorylation    |      |
|                     |                                        |            | Bcl-2 and Bcl-xl downregulation |      |
|                     |                                        |            | HIF-1α upregulation         |      |
|                     |                                        | HL-60 leukemia cells | Prevention of upregulation of HIF-1α | 279, 280 |
| DNA damage caused by cisplatin | No                                    | Jurkat leukemia cells | Inhibition of Caspases 3 and 9 activation | 282  |
|                     |                                        |            | Cytochrome c release        |      |
| DNA damage caused by UV | No                                    | KB epidermoid cells | Akt activation              | 284  |
| Fas                 | No                                     | KB epidermoid cells | Inhibition of Caspase-8 cleavage | 285  |
|                     |                                        |            | Bcl-2 phosphorylation       |      |
|                     |                                        |            | Cytochrome c release        |      |
| Microtubule interfering agents | No                                    | Jurkat leukemia cells | Suppression of Bcl-2 phosphorylation | 283  |
|                     |                                        |            | FasL expression             |      |
expression of TP was associated with complete demethylation of the CpG dinucleotides located in the TP promoter, which was demonstrated in breast carcinoma SKBR-3 cells. Low TP expression was correlated with hypermethylation of the CpG islands as in DLD-1 colon carcinoma cells. In DLD-1 cells, the expression of TP could be activated by demethylation with 5-aza-2'-deoxycytidine and to a lesser extent by histone deacetylation with trichostatin-A.310

Finally, also microenvironmental stress conditions, such as hypoxia and low pH stimulate the expression of TP.311 This clarifies why TP can be found in those parts of the tumor that are adjacent to necrotic areas or after occlusion of the tumor blood supply.311 In conclusion, stress-related factors, such as hypoxia and cytokines, induce the expression of TP, which indicates that this enzyme is a product of inflammation or microenvironmental stress.

6. TP INHIBITORS

Already in 1971, Judah Folkman postulated that tumor growth is angiogenesis-dependent and that tumor development and metastasis could be abolished by blocking the tumor blood supply.312 Currently, anti-angiogenic drugs, such as the VEGF-antibody bevacizumab (Avastin, Genentech/Roche, Basel Switzerland) and the kinase inhibitors sorafenib (Nexavar, Bayer, Leverkusen, Germany), and sunitinib (Sutent, Pfizer, New York, NY) are being used in cancer treatment while dozens of other anti-angiogenic molecules are evaluated clinically219,313 (for an update see: http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors). However, the benefits from these anti-angiogenic therapies are at the best temporary and mostly followed by resistance development of the tumor. Although tumor resistance may be caused by various mechanisms such as poor pharmacokinetics, limited drug uptake, increased drug efflux, and mutation of the target proteins, tumor resistance may also be caused by circumvention of the angiogenic blockade by activation and/or upregulation of alternative pro-angiogenic pathways in the tumor.313,314 For example, a study on glioblastoma patients treated with the VEGF receptor inhibitor cedinarib (Recentin, Astra Zeneca, London, UK) showed that the tumors evaded the anti-angiogenic therapy by upregulating the angiogenic fibroblast growth factor-2 (FGF-2) and stromal cell derived factor-1α (SDF-1α).315 Therefore, there is an urgent need to develop anti-angiogenic drugs directed at different angiogenic targets. As TP plays a fundamental role in cancer angiogenesis, many laboratories have tried to synthesize potent TP inhibitory drugs. Some of these molecules have been tested preclinically and clinically, but currently no product has been approved yet for clinical use. Therefore, only a few relevant inhibitors will be discussed. For a more extensive review on TP inhibitors, we refer to reference.316

A. Pyrimidine Analogues

For more than 30 years the only compounds known to inhibit TP were uracil derivatives, such as 6-aminouracil (6AT) and 6-amino-5-bromouracil (6A5BU) (Fig. 6). These molecules have 50% inhibitory concentration (IC50) values against the enzyme in the sub-micromolar range.317 When it became clear that TP is not only an enzyme involved in the nucleoside salvage pathway but is also implicated in angiogenesis, numerous laboratories aimed at synthesizing more potent TP inhibitors.

In 2000, Fukushima et al. identified “5-chloro-6-[1-(2-iminopyrrolidinyl)methyl] uracil hydrochloride (TPI)” (Fig. 6), the most potent inhibitor of human TP so far, with an IC50 value of 35 nM.318 This molecule was shown to abrogate several biological actions of TP. For example, TPI inhibited TP-induced angiogenesis in the mouse dorsal air sac assay. It also significantly reduced the tumor growth rate and microvessel density and increased...
the apoptotic index of KB/TP xenografted tumors. Furthermore, oral administration of TPI suppressed macroscopic liver metastases of highly metastatic KB/TP cells and also the level of human β-globin as a molecular marker of micrometastases in the livers of the mice. The fact that TPI is orally bio-available and has a strong nanomolar

Figure 6. Chemical structure of some illustrative inhibitors of TP.
inhibitory activity against TP suggests that this molecule might be a promising antitumor agent.

**B. Purine Analogues**

In 1998, Balzarini et al.\(^{319}\) described 7-deazaxanthine (7-DX) (Fig. 6) as the first purine derivative with inhibitory activity against a pyrimidine nucleoside phosphorylase (i.e. TP). The three-dimensional structure of *E. coli* TP was used for the rational modelling and design of 7-DX, which can be regarded as a pyrimidine at which a second ring was added to create extra stabilization. 7-DX not only efficiently inhibited the enzymatic activity of TP; it was also able to prevent neovascularization in the CAM assay.\(^{319}\)

The available crystal structure of *E. coli* TP has also led to the rational design of compounds that interact both with the thymine and the phosphate-binding site, the so-called multisubstrate analogue inhibitors of TP. These types of molecules consist of a base, interacting with the nucleoside-binding site and a phosphonate moiety that may bind to the phosphate-binding site. The distance between the thymine- and the phosphate-binding site of *E. coli* TP is estimated to be around 10 Å, therefore the thymine and the phosphonate moiety of these novel inhibitors were linked to each other with a spacer of 6–9 methylene entities. These compounds interact with both substrate-binding sites, and thus “freeze” the enzyme in an open, inactive conformation.\(^{320,321}\) TP65, which contains an alkyl phosphonate moiety covalently linked to 7-DX (Fig. 6), is such a multisubstrate inhibitor of TP, with an IC\(_{50}\) value in the micromolar range. This molecule could also abrogate biological activities of TP, such as angiogenesis in the CAM assay and the formation of microvascular sprouts from endothelial cell aggregates in a fibrin gel.\(^{222}\)

Another purine derivative that inhibits TP is 5'-O-tritylinosine (KIN59) (Fig. 6). KIN59 consists of a purine base (hypoxanthine), a ribose sugar and a trityl group at the 5'-position of the ribose. The trityl group of KIN59 has proven to be crucial for its inhibitory activity against TP and its anti-angiogenic effect in the CAM assay.\(^{322,323}\) KIN59 is in several ways a very unusual TP inhibitor. In the CAM assay, KIN59 not only prevented the formation of new blood vessels but also promoted the degradation of small pre-existing immature blood vessels. This effect was not due to unspecific cell toxicity. Furthermore, in contrast to all previously described TP inhibitors, this molecule does not compete with the natural substrates for binding to either the nucleoside- or the phosphate-binding site of TP, but interacts with a new, yet unknown, allosteric site of the enzyme in a non-competitive fashion.\(^{322}\) In order to identify the amino acids that interact with KIN59, computer-assisted modelling of the KIN59-TP complex was performed (unpublished data). This in silico analysis revealed a cavity in which KIN59 could fit in the vicinity of the Gly405-Val419 loop. In this pocket the amino acid Asp203 was found to play an important role for loop stabilization required for efficient enzyme catalysis. Site-directed mutagenesis of Asp203 to alanine yielded a TP with ~60-fold reduction in phosphorolytic capacity \((V_{\text{max}}/K_m)\) relative to the wild-type enzyme. Furthermore, KIN59 was not able to inhibit the enzymatic activity of the mutant TP, while the competitive inhibitors 6AT and 6A5BU maintained their inhibitory capacity.

**C. Prodrugs of TP Inhibitors**

Reigan et al. have explored a xanthine oxidase (XO) prodrug strategy. XO activity and expression are increased in hypoxic conditions. Moreover, increased XO activities are found in colorectal and prostate tumors as compared to their corresponding normal tissues. Therefore, 2'-nitro prodrugs of potent 2'-aminoimidazolyl TP inhibitors were developed. These prodrugs may become selectively activated by XO in the tumors and thus may exert
their TP inhibitory activity specifically within the hypoxic regions of the tumors.\textsuperscript{324} Also XO-sensitive prodrugs of 6A5BU, 7-DX, and TPI (Fig. 6) have been synthesized.\textsuperscript{325,326} The in vivo efficacy of these prodrug molecules remains to be investigated.

\textbf{D. 2-Deoxy-\textit{l}-Ribose}

2-Deoxy-\textit{l}-ribose (2DLR) is a stereoisomer of 2DDR. It is not a direct TP inhibitor because it does not inhibit the enzymatic activity of TP. However, this molecule is able to affect the biological effects of TP. Indeed, 2DLR suppresses the anti-apoptotic effect of 2DDR and prevents 2DDR-induced chemotaxis and tubulogenesis of bovine aortic endothelial cells in vitro. In vivo, 2DLR was able to abrogate TP-induced angiogenesis in the rat corneal assay and in the mouse dorsal air sac assay.\textsuperscript{223} Moreover, oral administration of 2DLR could significantly reduce the growth of KB/TP cells transplanted into nude mice and suppressed invasion and metastasis induced by KB/TP cells.\textsuperscript{273} Also the TP-induced activation of MMP-9 and secretion of IL-8 and VEGF could be blocked by 2DLR.\textsuperscript{257,273} The molecular basis of the biological effects of 2DLR remains, however, to be resolved.

\textbf{7. TP IN FLUOROPYRIMIDINE CHEMOTHERAPY}

\textbf{A. 5-Fluorouracil (5-FU)}

In 1957, Heidelberger et al. discovered the antitumor activity of 5-fluorouracil (5FU) (Fig. 7).\textsuperscript{327} Fifty years after its first synthesis, 5FU remains extensively used in the treatment of colorectal cancer. The possible metabolic pathways of 5FU are depicted in Figure 8. 5FU can elicit its antitumor activity by inhibiting thymidylate synthase (TS), which is responsible for the de novo thymidylate production and is thus a rate-limiting enzyme in DNA synthesis.\textsuperscript{328} First, 5FU needs to be converted by TP to 5-fluoro-2'-deoxyuridine (FdUrd). This action of TP can only take place if there is enough co-substrate (i.e. 2DDR-1P) for TP. Indeed, increase in the 2DDR-1P availability by addition of 2'-deoxy-pyrimidine nucleosides or 2'-deoxypurine nucleosides greatly enhances TP-mediated 5FU sensitivity of tumors.\textsuperscript{329–331} FdUrd is further converted by thymidine kinase (TK) to 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP). FdUMP can also be derived from FdUDP that is formed by reductive synthesis of FUDP, a reaction catalyzed by ribonucleotide reductase. FdUMP binds to both 5,10-methylenetetrahydrofolate (CH\textsubscript{2}THF) and TS leading to the formation of a ternary complex, which inhibits TS activity.\textsuperscript{332,333} As a result, dTTP pools get depleted, affecting DNA synthesis. FdUMP can also be further phosphorylated to FdUTP, which can be mis-incorporated into the DNA. Alternatively, 5FU may be converted directly or indirectly to 5-fluorouridine 5'-monophosphate (FUMP), which can be incorporated into RNA (upon conversion to its 5'-triphosphate derivative), resulting in inhibition of protein synthesis.\textsuperscript{328} The direct conversion of 5FU to FUMP by orotate phosphoribosyl transferase (OPRT) is considered to be the most important pathway for the activation of 5FU. 5FU cytotoxicity is not only determined by the above-described anabolic pathways but also by 5FU catabolism, i.e. 5FU is degraded by dihydropyrimidine dehydrogenase (DPD), which is abundantly found in the liver. This reaction is so fast that the plasma half-life of 5FU is only 6–20 min, i.e. more than 80\% of the administered 5FU is catabolized by DPD.\textsuperscript{334}

Several strategies have been explored to increase the anticancer activity of 5FU. One of these strategies is to enhance the binding of FdUMP to TS, which increases the cytotoxicity of 5FU. Administration of leucovorin (LV, Fig. 9), which is converted to CH\textsubscript{2}THF, increases the intracellular pools of CH\textsubscript{2}THF and stabilizes the FdUMP/TS complex. Studies have demonstrated that the addition of LV to bolus 5FU improves response rates compared to
single agent 5FU treatment (23 versus 11%) in patients with advanced colorectal cancer.\textsuperscript{335} 5FU/LV can be combined with oxaliplatin in a formulation known as FOLFOX, which is a frequently used therapy against metastatic colorectal cancer.\textsuperscript{336} Another approach to boost the bioavailability of 5FU is the inhibition of DPD, which causes the rapid breakdown of the fluorinated nucleobase derivative. The use of DPD inhibitors enables the oral use of 5FU because they almost completely prevent 5FU degradation in the gastrointestinal tract. 5-chloro-2,4-dihydropyrimidine (CDHP) is an example of such a frequently used DPD inhibitor,\textsuperscript{337} but also other DPD inhibitors such as (E)-5-(2-bromovinyl)uracil (BVU)\textsuperscript{338,339} and 5-ethynyluracil (eniluracil)\textsuperscript{340} have been reported. Efficient inactivation of DPD by oral administration of eniluracil has been observed in primary and metastatic colorectal cancer.\textsuperscript{341} However, eniluracil is currently withdrawn from further development because several studies showed that the combination of oral eniluracil and 5FU had lower activity compared to intravenous 5FU/LV treatment.\textsuperscript{342}

\textbf{B. 5FU-Prodrugs}

As 5FU has a poor oral bioavailability and is rapidly degraded by DPD, 5FU has to be administered via bolus injection or continuous intravenous administration. As these
infusional 5FU regimens are a costly, labor intensive approach and uncomfortable for the patients, large efforts have been made to design effective 5FU analogues suitable for oral administration. Ftorafur was the first designed oral 5FU prodrug (Fig. 7). This molecule is used in several combinations to improve its bioavailability. UFT, a 4:1 combination of uracil and Ftorafur, allows higher levels of circulating 5FU by saturating DPD with its natural substrate uracil. UFT is worldwide approved for the treatment of patients with colorectal cancers. Initially, TP was thought to play a role in the activation of Ftorafur. However, Ftorafur toxicity was not decreased by the TP inhibitor TPI or increased in cells with high TP levels. It is currently thought that this compound is converted by cytochrome P450 enzymes, which are expressed in the liver and in some colon carcinoma cell lines. The successor of UFT is S-1, which is a combination of Ftorafur, CDHP and potassium oxonate (OXO) in a molar ratio of 1:0.4:1. CDHP is a potent and reversible inhibitor of DPD. OXO reduces 5FU gastrointestinal toxicity by inhibiting OPRT, which activates 5FU.
OXO specifically accumulates in the gastrointestinal tract, thus preventing the activation of 5FU in the normal mucosa but not in the tumor. 5-fluoro-2'-deoxyuridine (FdUrd, floxuridine) is the deoxyribose metabolite of 5FU. As seen in Figure 8 it is a precursor of FdUMP, which inhibits TS. FdUrd can also be converted to 5FU in the liver by TP. Like 5FU, this molecule has a short plasma half-life (15 min) and causes gastrointestinal toxicity. Due to the higher toxicity, higher costs, and the equal efficacy of bolus injection of FdUrd compared to bolus 5FU, the use of FdUrd has been very limited. It is only occasionally used as a chemotherapeutic agent for hepatic arterial infusion in the treatment of unresectable liver metastases caused by colorectal cancer.

Another prodrug of 5FU is doxifluridine (5'-deoxy-5-fluorouridine, 5'DFUR), which requires TP for its one-step conversion to 5FU. Numerous in vitro studies showed that transfection of TP cDNA into tumor cells dramatically increases the sensitivity of the cells to 5'DFUR. Some studies also reported that TP enhances the activity of 5FU, but to a lesser extent than that of 5'DFUR. This is due to the fact that 5'DFUR only requires TP for the conversion to 5FU, while 5FU activation is mediated by at least three different pathways. As TP expression is also high in the gastrointestinal tract, 5'DFUR therapy resulted in dose-limiting toxicity, such as diarrhea.

Capecitabine (Xeloda, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine), an oral prodrug of 5FU, was designed to circumvent the gastrointestinal toxicity of 5'DFUR and to generate 5FU preferentially at the tumor site. The conversion of capecitabine to 5FU requires three distinct steps (see Fig. 8). Once oral capecitabine has passed the intestines in its intact form, it is hydrolyzed to 5'-deoxy-5-fluorocytidine (5'DFCR) by carboxylesterase in the liver. The second step is the conversion to 5'DFUR by cytidine deaminase, which is
localized in the liver and in various tumor types. Finally, 5′DFUR can be converted to 5FU in the tumors by TP\(^7\) (and UP\(^{356,357}\)). As TP is highly expressed in the tumor tissue, it permits the targeted intratumoral release of 5FU and consequently minimizes systemic toxicity.\(^{358−360}\) For example, in patients with colorectal cancer, it was proven that following oral administration of capecitabine, the 5FU concentration in the tumor tissue was 3.2 times higher than in adjacent nontumorigenic tissue and 21 times more elevated than in plasma.\(^{358}\) Furthermore, phase III trials enrolling patients with metastatic colorectal cancer showed that single agent capecitabine treatment is at least as effective as 5FU/LV therapy and is associated with significantly fewer clinically relevant toxicities.\(^{359−362}\) As capecitabine is at least as active as the 5FU/LV standard and better tolerated by the patients, it has become one of the most prescribed oral chemotherapeutic agents. Currently, capecitabine is approved by the US Food and Drug Administration (FDA) as an adjuvant in stage III Dukes’ C colorectal cancer and as first-line monotherapy in metastatic colon cancer. The drug is also accepted for use against metastatic breast cancer in combination with docetaxel after failure of anthracycline-based treatment or as monotherapy when patients have failed paclitaxel-based therapy. At the moment, the combination of capecitabine with different other anticancer agents such as bevacizumab, enzastaurin, and sorafenib is being evaluated in clinical trials.\(^{303,363−365}\)

As TP is the rate-limiting enzyme for the activation of capecitabine, it might be a useful predictor of tumor response to capecitabine-based chemotherapy. In colorectal\(^{366}\) and advanced non-small cell lung\(^{367}\) cancer, TP expression was associated with tumor response to capecitabine, while in patients with breast\(^{368}\) and gastric\(^{369}\) cancer the TP/DPD ratio showed a significant correlation with response to capecitabine therapy.

### C. Combination of TP-Inducible and TP-Targeted Therapy

As it has been shown in numerous transfection experiments that the antitumoral activity of 5′DFUR and capecitabine depends on their activation by TP, this enzyme is used as a target to enhance the anticancer activity of these fluoropyrimidines. As described in Section 5, TP levels can be elevated by several anticancer treatments, such as X-ray irradiation and chemotherapeutic agents (i.e. taxanes, mitomycin C, cyclophosphamide). It has been hypothesized that combination of TP-inducing therapies (such as taxanes) with TP-targeted therapy (such as capecitabine) would improve the clinical efficacy of these fluoropyrimidines. In the WiDr colon and MX-1 mammary human cancer xenograft models, the combination of X-ray irradiation with either capecitabine or 5′-DFUR showed a better antitumor effect than either radiation or chemotherapy alone.\(^{309}\) Furthermore, several clinical trials have demonstrated a synergy between capecitabine and TP-inducible chemotherapy. For example, in a large randomized phase-III trial on metastatic breast cancer it was demonstrated that the addition of capecitabine to docetaxel therapy results in an increased response rate, time to progression, and survival compared to standard treatment alone.\(^{370}\) Also the combination with other TP-inducible therapies, such as irinotecan, oxaliplatin, cisplatin, cyclophosphamide, paclitaxel, mitomycin C, and irradiation resulted in improved survival and time-to-progression compared to the monotherapy.\(^{7}\) The combination of capecitabine plus oxaliplatin (XELOX regimen) now represents a new standard of care for metastatic colon carcinoma.\(^{371}\)

### D. TFT

The fluoropyrimidine nucleoside 5-trifluorothymidine (TFT) was originally synthesized by Heidelberger et al. in 1964.\(^{372}\) TFT is phosphorylated by TK to its active monophosphate TFT-MP, which inhibits TS.\(^{373}\) In contrast to FdUMP, TFT-MP does not form a ternary complex with TS, but binds covalently to the active site of TS.\(^{374}\) TFT-MP can also be
further phosphorylated to TFT-TP, which can be incorporated into the DNA leading to cell death due to DNA strand break formation. Since 1980, TFT has been used for the topical treatment of epithelial keratitis caused by herpes simplex virus. This molecule has also been evaluated as an antitumor agent but the clinical studies were discontinued because of the high toxicity of TFT and its rapid degradation by TP that inactivates TFT by converting it to its inactive base. Given as a single agent, the plasma half-life of TFT is less than 20 min. Therefore, TFT was recently chosen to be combined with TPI, a very potent inhibitor of TP (see Section 6.A). This oral combination therapy, called TAS-102, combines TFT and TPI in a 1:0.5 molar ratio. The application of TFT together with TPI bypasses TFT degradation by TP resulting in increased TFT plasma levels compared to TFT alone. TAS-102 thus improves the bioavailability and thereby the efficacy of TFT. Another advantage of TAS-102 is that TPI might also abrogate the angiogenic properties of TP. Furthermore, TAS-102 can also be used against cancers that are resistant to 5FU, as shown by in vitro studies and tumor implants in nude mice. So far, several phase I clinical trials using TAS-102 have been completed. The toxicities observed were granulocytopenia, nausea, vomiting, diarrhea, fatigue, and rash. A phase I clinical trial demonstrated that TAS-102 is active against heavily pretreated metastatic breast cancers. However, in a recent phase I trial, where TAS-102 was administered daily on a 5-day-a-week schedule to patients with solid (mostly colorectal) tumors, patients treated with TAS-102 showed no objective response although stable disease was seen in 18 of 61 patients. Currently, phase II trials of TAS-102 alone or in combination with other therapies against breast, gastrointestinal, and other solid tumors are ongoing. The combination of TFT together with oxaliplatin was tested in vitro in various colon carcinoma cell lines and strong synergism was observed. These results provide a motivation for the clinical study of TAS-102 together with oxaliplatin in the treatment of colorectal cancer.

E. Mycoplasmal TP and Fluoropyrimidines

TP is not only present in humans; TP activity was also detected in different Mycoplasma species. Mycoplasmas are the smallest self-replicating bacteria, which can cause respiratory and urogenital diseases. Most mycoplasmal infections remain, however, unidentified, because many people seem to be chronically infected without apparent clinical symptoms. Mycoplasmas might also play a role in cancer. Mycoplasmal infections are associated with leukaemia and ovarian and cervical cancer. In particular, the species is frequently found in tissues of gastric, colon, esophageal, lung, and breast cancer, but not in analogous nontumorigenic tissue. Chronic and persistent infections with mycoplasmas affect many biological characteristics of mammalian cells and can even lead to malignant transformations. The -encoded protein p37 was shown to alter gene expression, growth, and migratory potential of prostate cancer cell lines in vitro. p37 was also found to promote cancer cell invasiveness and metastasis by activation of MMP-2 and by phosphorylation of the epidermal growth factor receptor. Moreover, in an experimental metastasis mouse model, p37-encoding adenovirus-infected mouse melanoma B16F10 cells formed more metastatic lesions than the parental cell line.

Recently, it was shown that TP encoded by not only catalyzes the conversion of thymidine to thymine, but also efficiently recognizes FdUrd, TFT, and 5’DFUR. As a result, the cytostatic activity of FdUrd and TFT was significantly decreased in MCF-7 breast carcinoma cells infected with compared to control MCF-7 cells. The sensitivity to 5FU was not altered by mycoplasmal infection while 5’DFUR was at least 30-fold more cytostatic in mycoplasma-infected MCF-7 cells, suggesting that
mycoplasma-encoded TP activated this molecule. Addition of the TP inhibitor TPI or the mycoplasma-specific antibiotic plasmocin could restore the altered cytostatic activity.\textsuperscript{389,400} Also HCT116 colon cancer cells infected with mycoplasma were 5- and 100-fold more resistant to 5-FU and FdUrd, respectively, than the parental noninfected cells.\textsuperscript{401} These data demonstrate that the presence of mycoplasma and thus mycoplasmal TP may severely affect the cytostatic efficacy of FdUrd, TFT (and 5FU), suggesting that the combination of these anticancer agents with a specific antibiotic against mycoplasmas might improve the efficacy of these drugs.\textsuperscript{389,400}

8. CONCLUSIONS AND PERSPECTIVES

There is compelling evidence that the intracellular enzyme TP plays an essential role in tumor progression. TP stimulates tumor growth by protecting tumor cells from apoptosis and by inducing angiogenesis. Although many investigators have tried to unravel the molecular mechanisms through which TP exerts these biological effects, more research needs to be done to gain more detailed insight into the signal transduction cascades induced by TP and its product metabolite 2DDR. This knowledge could offer crucial information for the rational development of strategies to inhibit the protumoral actions of TP. Indeed, as TP expression is elevated in numerous tumor types, inhibition of TP activity might offer a potential strategy in the battle against cancer. In this respect, more potent TP inhibitors need to be synthesized and (pre)clinically evaluated as TPI is currently the only available TP inhibitor that is being investigated in clinical trials. As such, the results of the phase II clinical trials with TAS-102 will be of particular interest, as they will provide important information on the impact of TP inhibitors on tumor growth in cancer patients.

Recent data have shown that tumors treated with anti-angiogenic monotherapy seem to escape drug treatment by upregulating and/or activating alternative angiogenic pathways. Therefore, future strategies should favor the concomittant attack of multiple targets by combining different anti-angiogenic molecules or anti-angiogenic molecules with radio- and/or chemotherapy. Thus, TP presents an alternative target or an additional target to existing anticancer therapies. The potential use of TP inhibitors is not limited to cancer as TP is also involved in many inflammatory diseases, such as RA. Also these patients might thus benefit from treatment with TP-inhibitory drugs and the application of TP inhibitors in the treatment of inflammatory diseases should be further explored.

However, the use of TP inhibitors in the treatment of cancer should be carefully and cautiously considered, because TP activity is required for the activation of the commonly used 5FU-prodrug capecitabine. Thus, TP inhibitors should not be combined with such TP-activation-dependent therapeutic agents. One possible strategy to overcome this problem might be to inhibit the downstream mediators of TP instead of directly inhibiting TP activity per se. 2DLR has been shown to inhibit the biological actions of TP without affecting its enzymatic activity and therefore it might be a good candidate for combination with fluoropyrimidine chemotherapy. However, as TP fulfills a key role in capecitabine activation, most investigations have explored the combination of TP-upregulating therapies with capecitabine Clinical trials combining capecitabine with TP-inducible therapies showed that combination of both therapies results in a higher antitumor efficacy than monotherapy of either agents.

In conclusion, TP may play a dual role in cancer development and therapy: TP stimulates tumor growth but at the same time it is also required to activate the chemotherapeutic agent capecitabine. Depending on the type of the tumor and the nature of the therapeutic agents, cancer patients may benefit from TP-inducible therapies or TP inhibitory drugs.
9. ABBREVIATIONS

BVDU  5-(E)-(2-bromovinyl)-2'-deoxyuridine
CAM  chorio-allantoic membrane
CDHP  5-chloro-2,4-dihydropyrimidine
CH$_2$THF  5,10-methylenetetrahydrofolate
2DDR  2-deoxy-D-ribose
2DDR-1P  2-deoxy-D-ribose-1-phosphate
5'DFUR  5-fluoro-5'-deoxyuridine
2DLR  2-deoxy-L-ribose
DPD  dihydropyrimidine dehydrogenase
ECM  extracellular matrix
EPC  endothelial progenitor cell
FAK  focal adhesion kinase
FdUMP  5-fluoro-2'-deoxyuridine 5'-monophosphate
FdUrd  5-fluoro-2'-deoxyuridine
FLS  fibroblast-like synoviocytes
5FU  5-fluorouracil
HIF-1$\alpha$  hypoxia-inducible factor-1$\alpha$
HO-1  heme-oxygenase-1
HUVEC  human umbilical vein endothelial cell
IC$_{50}$  50% inhibitory concentration
IFN-$\gamma$  interferon-$\gamma$
IL  interleukin
LV  leucovorin
MMP  matrix metalloproteinase
MNGIE  mitochondrial neurogastrointestinal encephalomyopathy
OPRT  orotate phosphoribosyl transferase
OXO  potassium oxonate
PD-ECGF  platelet-derived-endothelial cell growth factor
PRPP  phosphoribosyl pyrophosphate
RA  rheumatoid arthritis
RR  ribonucleotide reductase
TAM  tumor-associated macrophage
TFT  5-trifluorothymidine
TK  thymidine kinase
TP  thymidine phosphorylase
TPI  5-chloro-6-[1-(2-iminopyrrolidinyl)methyl] uracil hydrochloride
TS  thymidylate synthase
UP  uridine phosphorylase
VEGF  vascular endothelial growth factor
VSMC  vascular smooth muscle cell
XO  xanthine oxidase

ACKNOWLEDGMENTS

Annelies Bronckaers benefits from a Ph.D. scholarship of the FWO. Sandra Liekens is a postdoctoral fellow of the FWO. The research of the authors on TP was supported by grants of the Centers of Excellence of the K.U. Leuven (Krediet no. 05/15) (to J.B. and S.L.), the
REFERENCES

1. Friedkin M, Roberts D. The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J Biol Chem 1954;207:245–256.
2. Iltzsch MH, El Kouni MH, Cha S. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry 1985;24:6799–6807.
3. Schwartz M. Thymidine phosphorylase from Escherichia coli. Properties and kinetics. Eur J Biochem 1971;21:191–198.
4. Desgranges C, Razaka G, Rabaud M, Bricaud H, Balzarini J, De Clercq E. Phosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted-2'-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets. Biochem Pharmacol 1983;32:3583–3590.
5. Heidelberger C, Anderson S. Fluorinated pyrimidines. XXI. The tumor-inhibitory activity of 5-triflyromethyl-2'-deoxyuridine. Cancer Res 1964;24:1979–1985.
6. Schwartz EL, Baptiste N, Wadler S, Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995;270:19073–19077.
7. Walko CM, Lindley C. Capecitabine: A review. Clin Ther 2005;27:23–44.
8. Miyazono K, Okabe T, Urabe A, Takaku F, Heldin CH. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 1987;262:4098–4103.
9. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989;338:557–562.
10. Moghaddam A, Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 1992;31:12141–12146.
11. Usuki K, Saras J, Waltenberger J, Miyazono K, Pierce G, Thomason A, Heldin CH. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun 1992;184:1311–1316.
12. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y. Angiogenic factor. Nature 1992;356:668.
13. Asai K, Hirano T, Kaneko S, Moriyama A, Nakanishi K, Isobe I, Eksioglu YZ, Kato T. A novel glial growth inhibitory factor, giotstatin, derived from neurofibroma. J Neurochem 1992;59:307–317.
14. Asai K, Nakanishi K, Isobe I, Eksioglu YZ, Hirano A, Hama K, Miyamoto T, Kato T. Neurotrophic action of giotstatin on cortical neurons. Identity of giotstatin and platelet-derived endothelial cell growth factor. J Biol Chem 1992;267:20311–20316.
15. Blank JG, Hoffie PA. Purification and properties of thymidine phosphorylase from Salmonella typhimurium. Arch Biochem Biophys 1975;168:259–265.
16. Voytek P. Purification of thymidine phosphorylase from Escherichia coli and its photoactivation in the presence of thymine, thymidine, and some halogenated analogs. J Biol Chem 1975;250:3660–3665.
17. Kubilus J, Lee LD, Baden HP. Purification of thymidine phosphorylase from human amnionchorion. Biochim Biophys Acta 1978;527:221–228.
18. Barton GJ, Ponting CP, Spraggion G, Finnis C, Sleep D. Human platelet-derived endothelial cell growth factor is homologous to Escherichia coli thymidine phosphorylase. Protein Sci 1992;1:688–690.
19. Schwartz M. Thymidine phosphorylase from Escherichia coli. Methods Enzymol 1978;51:442–445.
20. Desgranges C, Razaka G, Rabaud M, Bricaud H. Catabolism of thymidine in human blood platelets: Purification and properties of thymidine phosphorylase. Biochim Biophys Acta 1981;654:211–218.

21. Walter MR, Cook WJ, Cole LB, Short SA, Koszalka GW, Krenitsky TA, Ealick SE. Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 A resolution. J Biol Chem 1990;265:14016–14022.

22. Pugmire MJ, Cook WJ, Jasanoff A, Walter MR, Ealick SE. Structural and theoretical studies suggest domain movement produces an active conformation of thymidine phosphorylase. J Mol Biol 1998;281:285–299.

23. Pugmire MJ, Ealick SE. The crystal structure of pyrimidine nucleoside phosphorylase in a closed conformation. Structure 1998;6:1467–1479.

24. Mendieta J, Martin-Santamaria S, Priego EM, Balzarini J, Camarasa MJ, Pérez-Pérez MJ, Gago F. Role of histidine-85 in the catalytic mechanism of thymidine phosphorylase as assessed by targeted molecular dynamics simulations and quantum mechanical calculations. Biochemistry 2004;43:405–414.

25. Norman RA, Barry ST, Bate M, Breed J, Colls JG, Ernill RJ, Luke RW, Minshull CA, McAlister MS, McCall EJ, McMiken HH, Paterson DS, Timms D, Tucker JA, Paupitit RA. Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor. Structure 2004;12:75–84.

26. Spraggon G, Stuart D, Ponting C, Finnis C, Sleep D, Jones Y. Crystallization and X-ray diffraction study of recombinant platelet-derived endothelial cell growth factor. J Mol Biol 1993;234:879–880.

27. El Omari K, Bronckaers A, Liekens S, Pérez-Pérez MJ, Balzarini J, Stammers DK. Structural basis for non-competitive product inhibition in human thymidine phosphorylase: Implications for drug design. Biochem J 2006;399:199–204.

28. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, Harris AL. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study. J Pathol 1995;176:183–190.

29. Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K, Akiyama S. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochim Biophys Acta 1990;1034:107–113.

30. Matsukawa K, Moriyama A, Kawai Y, Asai K, Kato T. Tissue distribution of human gliostatin/platelet-derived endothelial cell growth factor (PD-ECGF) and its drug-induced expression. Biochim Biophys Acta 1996;1314:71–82.

31. Shaw T, Smillie RH, MacPhee DG. The role of blood platelets in nucleoside metabolism: Assay, cellular location and significance of thymidine phosphorylase in human blood. Mutat Res 1988;200:99–116.

32. Jackson MR, Carney EW, Lye SJ, Ritchie JW. Localization of two angiogenic growth factors (PDECGF and VEGF) in human placentae throughout gestation. Placenta 1994;15:341–353.

33. Usuki K, Norberg L, Larsson E, Miyazono K, Hellman U, Wernstedt C, Rubin K, Heldin CH. Localization of platelet-derived endothelial cell growth factor in human placenta and purification of an alternatively processed form. Cell Regul 1990;1:577–584.

34. Zhang L, MacKenzie IZ, Rees MC, Bicknell R. Regulation of the expression of the angiogenic enzyme platelet-derived endothelial cell growth factor/thymidine phosphorylase in endometrial isolates by ovarian steroids and cytokines. Endocrinology 1997;138:4921–4930.

35. Fujimoto J, Ichigo S, Sakaguchi H, Hirose R, Tamaya T. Expression of platelet-derived endothelial cell growth factor and its mRNA in uterine endometrium during the menstrual cycle. Mol Hum Reprod 1998;4:509–513.

36. Abbas MM, Evans JJ, Sykes PH, Benny PS. Modulation of vascular endothelial growth factor and thymidine phosphorylase in normal human endometrial stromal cells. Fertil Steril 2004;82:1048–1053.
37. Osuga Y, Toyoshima H, Mitsuhashi N, Taketani Y. The presence of platelet-derived endothelial cell growth factor in human endometrium and its characteristic expression during the menstrual cycle and early gestational period. Hum Reprod 1995;10:989–993.

38. Creamer D, Jaggar R, Allen M, Bicknell R, Barker J. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 1997;137:851–855.

39. Hammerberg C, Fisher GJ, Voorhees JJ, Cooper KD. Elevated thymidine phosphorylase activity in psoriatic lesions accounts for the apparent presence of an epidermal “growth inhibitor,” but is not in itself growth inhibitory. J Invest Dermatol 1991;97:286–290.

40. Giatromanolaki A, Sivridis E, Maltezos E, Papazoglou D, Simopoulos C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia inducible factor lalpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol 2003;56:209–213.

41. Saito S, Tsuno NH, Sunami E, Horii N, Kitayama J, Kazama S, Okaji Y, Kawai K, Kanazawa T, Watanabe T, Shibata Y, Nagawa H. Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease. J Gastroenterol 2003;38:229–237.

42. Wang EH, Goh YB, Moon IS, Park CH, Lee KH, Kang SH, Kang CS, Choi YJ. Upregulation of thymidine phosphorylase in chronic glomerulonephritis and its role in tubulointerstitial injury. Nephron Clin Pract 2006;102:e13–e142.

43. Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan TP. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol 2000;192:234–242.

44. Takeuchi M, Otsuka T, Matsui N, Asai K, Hirano T, Moriyama A, Isobe I, Eksioglu YZ, Matsukawa K, Kato T. Aberrant production of glistatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum 1994;37:662–672.

45. Asai K, Hirano T, Matsukawa K, Kusada J, Takeuchi M, Otsuka T, Matsui N, Kato T. High concentrations of immunoreactive glistatin/platelet-derived endothelial cell growth factor in synovial fluid and serum of rheumatoid arthritis. Clin Chim Acta 1993;218:1–4.

46. Waguri Y, Otsuka T, Sugimura I, Matsui N, Asai K, Moriyama A, Kato T. Glistatin/platelet-derived endothelial cell growth factor as a clinical marker of rheumatoid arthritis and its regulation in fibroblast-like synoviocytes. Br J Rheumatol 1997;36:315–321.

47. Waguri-Nagaya Y, Otsuka T, Sugimura I, Matsui N, Asai K, Nakajima K, Tada T, Akiyama S, Kato T. Synovial inflammation and hyperplasia induced by glistatin/platelet-derived endothelial cell growth factor in rabbit knees. Rheumatol Int 2000;20:13–19.

48. Muro H, Waguri-Nagaya Y, Mukofujiwara Y, Iwashashi T, Otsuka T, Matsui N, Moriyama A, Asai K, Kato T. Autocrine induction of glistatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) and GLS-induced expression of matrix metalloproteinases in rheumatoid arthritis synoviocytes. Rheumatology (Oxford) 1999;38:1195–1202.

49. Ieda Y, Waguri-Nagaya Y, Iwashasi T, Otsuka T, Matsui N, Namba M, Asai K, Kato T. IL-1beta-induced expression of matrix metalloproteinases and glistatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) in a chondrosarcoma cell line (OUMS-27). Rheumatol Int 2001;21:45–52.

50. Tanikawa T, Waguri-Nagaya Y, Kusabe T, Aoyama M, Asai K, Otsuka T. Glistatin/thymidine phosphorylase-regulated vascular endothelial growth-factor production in human fibroblast-like synoviocytes. Rheumatol Int 2007;27:553–559.

51. Hirano M, Silvestri G, Blake DM, Lombes A, Minetti C, Bonilla E, Hays AP, Lovelace RE, Butler I, Bertorini TE. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994;44:721–727.

52. Nishino I, Spinazzola A, Papadimitriou A, Hammans S, Steiner I, Hahn CD, Connolly AM, Verloes A, Guimaraes J, Maillard I, Hamano H, Donati MA, Semrad CE, Russell JA, Andreu AL, Hadjigeorgiou GM, Vu TH, Tadesse S, Nygaard TG, Nonaka I, Hirano I, Bonilla E, Rowland LP.
DiMauro S, Hirano M. Mitochondrial neurogastrointestinal encephalomyopathy: An autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 2000;47:792–800.

53. Spinazzola A, Marti R, Nishino I, Andreu AL, Naini A, Tadesse S, Pela I, Zammarchi E, Donati MA, Oliver JA, Hirano M. Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 2002;277:4128–4133.

54. Marti R, Nishigaki Y, Hirano M. Elevated plasma deoxyuridine in patients with thymidine phosphorylase deficiency. Biochem Biophys Res Commun 2003;303:14–18.

55. Valentino ML, Marti R, Tadesse S, Lopez LC, Manes JL, Lyzak J, Hahn A, Carelli V, Hirano M. Thymidine and deoxyuridine accumulate in tissues of patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). FEBS Lett 2007;581:3410–3414.

56. Haraguchi M, Tsujimoto H, Fukushima M, Higuchi I, Kuribayashi H, Utsumi H, Nakayama A, Hashizume Y, Hirato J, Yoshida H, Harai H, Hamano S, Kawaguchi H, Furukawa T, Miyazono K, Ishikawa F, Toyoshima H, Kaname T, Komatsu M, Chen ZS, Gotanda T, Tachiwada T, Sumizawa T, Miyadera K, Osame M, Yoshida H, Noda T, Yamada Y, Akiyama S. Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice. Mol Cell Biol 2002;22:5212–5221.

57. Lopez LC, Akman HO, Garcia-Cazorla A, Dorado B, Marti R, Nishino I, Tadesse S, Pizzorno G, Shungu D, Bonilla E, Tanji K, Hirano M. Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase deficient mice. Hum Mol Genet 2009;18:714–722.

58. Hirano M, Nishigaki Y, Marti R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): A disease of two genomes. Neurologist 2004;10:8–17.

59. Kumagai Y, Sugiura Y, Sugeno H, Takebayashi Y, Takenoshita S, Yamamoto T. Thymidine phosphorylase gene mutation is not a primary cause of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Intern Med 2006;45:443–446.

60. Dickinson EK, Adams DL, Schon EA, Glerum DM. A human SCO2 mutation helps define the role of Sco1p in the cytochrome oxidase assembly pathway. J Biol Chem 2000;275:26780–26785.

61. Jaksch M, Ogilvie I, Yao J, Kortenhaus G, Bresser HG, Gerbitz KD, Shoubridge EA. Mutations in SCO2 are associated with a distinct form of hypertrophic cardiomyopathy and cytochrome c oxidase deficiency. Hum Mol Genet 2000;9:795–801.

62. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999;283:689–692.

63. Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995;92:998–1002.

64. Arima J, Imazono Y, Takebayashi Y, Nishiyama K, Shirahama T, Akiba S, Furukawa T, Akiyama S, Ohn Y. Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 2000;88:1131–1138.

65. O'Brien TS, Fox SB, Dickinson AJ, Turley H, Westwood M, Moghaddam A, Gatter KC, Bicknell R, Harris AL. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 1996;56:4799–4804.

66. Yoshikawa T, Suzuki K, Kobayashi O, Sairenji M, Motohashi H, Tsuburaya A, Nakamura Y, Shimizu A, Yanoma S, Noguchi Y. Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer. Br J Cancer 1999;79:1145–1150.

67. Takebayashi Y, Miyadera K, Akiyama S, Hokita S, Yamada K, Akiba S, Yamada Y, Sumizawa T, Aikou T. Expression of thymidine phosphorylase in human gastric carcinoma. Jpn J Cancer Res 1996;87:288–295.

68. Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y, Akiyama S, Aikou T. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 1996;32A:1227–1232.

Medicinal Research Reviews DOI 10.1002/med
69. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K, Harris AL. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000;82:1427–1432.

70. Takebayashi Y, Natsugoe S, Baba M, Akiba S, Fukumoto T, Miyadera K, Yamada Y, Takao S, Akiyama S, Aikou T. Thymidine phosphorylase in human esophageal squamous cell carcinoma. Cancer 1999;85:282–289.

71. Fujimoto J, Sakaguchi H, Hirose R, Wen H, Tamaya T. Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers. Cancer Res 1999;59:3041–3044.

72. Yamamoto A, Dhar DK, El Assal ON, Igarashi M, Tabara H, Nagasue N. Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma. J Hepatol 1998;29:290–299.

73. Mainou-Fowler T, Angus B, Miller S, Proctor SJ, Taylor PR, Wood KM. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma 2006;47:223–230.

74. Slager EH, Honders MW, van der Meijden ED, Luxemburg-Heijs SA, Kloosterboer FM, Kester MG, Jedema I, Marijt WA, Schaafsma MR, Willemze R, Valkenburg JH. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 2006;107:4954–4960.

75. Fujimoto J, Ichigo S, Sakaguchi H, Hirose R, Tamaya T. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers. Cancer Lett 1998;130:115–120.

76. Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, Tsuji S, Nakajima S, Doi R, Imamura M. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1998;34:1439–1447.

77. Fujioka S, Yoshida K, Yanagisawa S, Kawakami M, Aoki T, Yamazaki Y. Angiogenesis in pancreatic carcinoma: Thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 2001;92:1788–1797.

78. Fujiwaki R, Hata K, Iida K, Koike M, Miyazaki K. Immunohistochemical expression of thymidine phosphorylase in human endometrial cancer. Gynecol Oncol 1998;68:247–252.

79. Fujiwaki R, Hata K, Iida K, Maede Y, Watanabe Y, Koike M, Miyazaki K. Co-expression of vascular endothelial growth factor and thymidine phosphorylase in endometrial cancer. Acta Obstet Gynecol Scand 1999;78:728–734.

80. Han HS, Hwang TS. Angiogenesis in gastric cancer: Importance of the thymidine phosphorylase expression of cancer cells as an angiogenic factor. Oncol Rep 2007;17:61–65.

81. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999;79:1553–1563.

82. Ikeyashiki M, Sakatani T, Ueta T, Fukuda K, Yamaguchi K, Tsujitani S, Kaibara N. The expression of thymidine phosphorylase suppresses spontaneous apoptosis of cancer cells in esophageal squamous cell carcinoma. Pathobiology 2001;69:36–43.

83. Jinmet F, Kimura W, Sakurai F, Mori Y, Mizutani M, Hiraizumi I. Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas. Hepatogastroenterology 2007;54:1635–1640.

84. Takei Y, Maehara Y, Tomoda M, Kabashima A, Oda S, Ooshiro T, Baba H, Kohnoe S, Sugimachi K. Thymidine phosphorylase activity and angiogenesis in gastric cancer. Oncol Rep 1999;6:995–999.

85. Kikuyama S, Inada T, Shimizu K, Miyakita M. Thymidine phosphorylase expression in gastric cancer in association with proliferative activity and angiogenesis. Anticancer Res 2000;20:2081–2086.
86. Kimura H, Konishi K, Nukui T, Kaji M, Maeda K, Yabushita K, Tsuji M, Miwa A. Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J Surg Oncol 2001;76:31–36.

87. Kimura H, Konishi K, Kaji M, Maeda K, Yabushita K, Miwa A. Correlation between expression levels of thymidine phosphorylase (dThdPase) and clinical features in human gastric carcinoma. Hepatogastroenterology 2002;49:882–886.

88. Konno S, Takebayashi Y, Aiba M, Akiyama S, Ogawa K. Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma. Cancer Lett 2001;166:103–111.

89. Konno S, Takebayashi Y, Higashimoto M, Katsube T, Kanzaki A, Kawahara M, Takenoshita S, Aiba M, Ogawa K. Thymidine phosphorylase expression in gastric carcinoma as a marker for metastasis. Anticancer Res 2003;23:5011–5014.

90. Kuwahara K, Sasaki T, Kuwada Y, Murakami M, Yamasaki K, Chayama K. Expressions of angiogenic factors in pancreatic ductal carcinoma: A correlative study with clinicopathologic parameters and patient survival. Pancreas 2003;26:344–349.

91. Liakakos T, Troupis T, Ghiconti I, Triantafyllidis S, Macheras A, Karatzas G, Pavlakis K. Immunohistochemical localization of thymidine phosphorylase in gastric cancer: Is there a role of the differential expression in tumor cells and associated stromal cells? Anticancer Res 2006;26:3899–3903.

92. Mazurek A, Kuc P, Terlikowski S, Laudanski T. Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer. Neoplasma 2006;53:242–246.

93. Mazurek A, Kuc P, Mazurek-Wadolkowska E, Laudanski T. A role of thymidine phosphorylase and P53 tissue protein expression in biology of endometrial cancer. Neoplasma 2008;55:261–265.

94. Miyake K, Imura S, Yoshizumi T, Ikemoto T, Morine Y, Shimada M. Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer. Int J Clin Oncol 2007;12:111–119.

95. Noguchi T, Fujiwara S, Takeno S, Kai S, Mizuta A, Nagao Y, Uchida Y. Clinical impact of thymidine phosphorylase expression in gastric cancer. Oncol Rep 2003;10:561–566.

96. Ogawa K, Konno S, Takebayashi Y, Miura K, Katsube T, Kajiwara T, Aiba M, Aikou T, Akiyama S. Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma. Anticancer Res 1999;19:4363–4367.

97. Sakamoto H, Shirakawa T, Izuka S, Igarashi T, Kinoshita K, Ohtani K, Takami T, Nakayama Y, Teramoto K, Satoh K. Thymidine phosphorylase expression is predominantly observed in stroma of well-differentiated adenocarcinoma of endometrium and correlates with a frequency of vascular involvement. Gynecol Oncol 1999;72:298–305.

98. Seki N, Kodama J, Hongo A, Miyagi Y, Yoshinouchi M, Kudo T. Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in endometrial cancer. Int J Oncol 1999;15:781–786.

99. Seki N, Kodama J, Hongo A, Miyagi Y, Yoshinouchi M, Kudo T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer. Eur J Cancer 2000;36:68–73.

100. Shimaoka S, Matsushita S, Nitanda T, Matsuda A, Nioh T, Suenaga T, Nishimata Y, Akiba S, Akiyama S, Nishimata H. The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma. Cancer 2000;88:2220–2227.

101. Sivridis E, Giatromanolaki A, Koukourakis MI, Bicknell R, Harris AL, Gatter KC. Thymidine phosphorylase expression in endometrial carcinomas. Clin Exp Metastasis 1999;17:445–450.
103. Takao S, Takebayashi Y, Che X, Shinchi H, Natsugoe S, Miyadera K, Yamada Y, Akiyama S, Aikou T. Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas. Clin Cancer Res 1998;4:1619–1624.

104. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Suzuki M, Terao T. Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer. Hum Pathol 2002;33:1105–1113.

105. Tokumo K, Kodama J, Seki N, Nakanishi Y, Miyagi Y, Kamimura S, Yoshinouchi M, Okuda H, Kudo T. Different angiogenic pathways in human cervical cancers. Gynecol Oncol 1998;68:38–44.

106. Tsujitani S, Saito H, Maeta Y, Yamaguchi K, Tatebe S, Kondo A, Kaibara N. Neoangiogenesis in patients with gastric carcinoma in relation to the expression of vascular endothelial growth factor and thymidine phosphorylase. Anticancer Res 2004;24:1853–1859.

107. Giatromanolaki A, Koukourakis MI, Kakolyris S, Kaklamanis L, Barbatis K, O‘Byrne KJ, Theodossiou D, Harris AL, Gatter KC. Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer. Anticancer Res 1998;18:71–76.

108. Fujimoto J, Ichigo S, Sakaguchi H, Hirose R, Tamaya T. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers. Cancer Lett 1998;126:83–88.

109. Igarashi M, Dhar DK, Kubota H, Yamamoto A, El Assal O, Naganuma N. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer 1998;82:1225–1232.

110. Nakayama Y, Sueishi K, Oka K, Kono S, Tomonaga M. Stromal angiogenesis in human glioma: A role of platelet-derived endothelial cell growth factor. Surg Neurol 1998;49:181–187.

111. Saeki T, Tanada M, Takashima S, Saeki H, Takiyama W, Nishimoto N, Moriwaki S. Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas. Jpn J Clin Oncol 1997;27:227–230.

112. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. J Pathol 1997;182:414–420.

113. Imazano Y, Takebayashi Y, Nishiyama K, Akiba S, Miyadera K, Yamada Y, Akiyama S, Ohi Y. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 1997;15:2570–2578.

114. Kubota Y, Miura T, Moriyma M, Noguchi S, Matsuzaki J, Takebayashi S, Hosaka M. Thymidine phosphorylase activity in human bladder cancer: Difference between superficial and invasive cancer. Clin Cancer Res 1997;3:973–976.

115. Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC, Harris AL. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 1997;8:271–275.

116. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963–969.

117. Toi M, Gion M, Biganzoli E, Dittadi R, Boracchi P, Miceli R, Meli S, Mori K, Tominaga T, Gasparini G. Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications. Angiogenesis 1997;1:71–83.
119. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC, Harris AL. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 1997;75:477–481.

120. Tanigawa N, Amaya H, Matsumura M, Katoh Y, Kitaoka A, Aotake T, Shimomatsuya T, Rosenwasser OA, Iki M. Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Lett 1997;108:281–290.

121. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F, Aikou T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996;88:1110–1117.

122. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Onoda N, Kato Y, Sowa M. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 1996;73:884–888.

123. Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC, Harris AL. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 1996;73:275–280.

124. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer 1995;64:79–82.

125. Sugamoto T, Tanji N, Nishio S, Yokoyama M. Expression of platelet-derived endothelial cell growth factor in prostatic adenocarcinoma. Oncol Rep 1999;6:519–522.

126. Yamagata M, Mori M, Mimori K, Mafune KI, Tanaka Y, Ueo H, Akiyoshi T. Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer. Br J Cancer 1999;79:565–569.

127. Mimori K, Ueo H, Shirasaka C, Shiraishi T, Yamagata M, Haraguchi M, Mori M. Up-regulated pyrimidine nucleoside phosphorylase in breast carcinoma correlates with lymph node metastasis. Ann Oncol 1999;10:111–113.

128. Mizutani Y, Okada Y, Yoshioka O. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 1997;79:1190–1194.

129. Alcalde RE, Terakado N, Otsuki K, Matsumura T. Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma. Oncology 1997;54:324–328.

130. Kodama J, Seki N, Tokumo K, Hongo A, Miyagi Y, Yoshinouchi M, Okuda H, Kudo T. Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer. Oncol Rep 1999;6:617–620.

131. Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers. Br J Cancer 1999;79:1249–1254.

132. Hata K, Nagami H, Iida K, Miyazaki K, Collins WP. Expression of thymidine phosphorylase in malignant ovarian tumors: Correlation with microvessel density and an ultrasound-derived index of angiogenesis. Ultrasound Obstet Gynecol 1998;12:201–206.

133. Volm M, Mattern J, Koomagi R. Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: Relationship to various biological factors. Int J Oncol 1998;13:975–979.

134. Sawase K, Nomata K, Kanetake H, Saito Y. The expression of platelet-derived endothelial cell growth factor in human bladder cancer. Cancer Lett 1998;130:35–41.

135. Nagaoka H, Iino Y, Takei H, Morishita Y. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. Int J Oncol 1998;13:449–454.

136. Fujieda S, Sunaga H, Tsuzuki H, Tanaka N, Saito H. Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma. Clin Cancer Res 1998;4:1583–1590.

137. Matsumura M, Chiba Y, Lu C, Amaya H, Shimomatsuya T, Horiuchi T, Muraoka R, Tanigawa N. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression
correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer. Cancer Lett 1998;128:55–63.

138. Koukourakis MI, Giatromanolaki A, Kakolyris S, O’Byrne KJ, Apostolis N, Skarlatos J, Gatter KC, Harris AL. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: Impact on tumour neoangiogenesis and survival. Br J Cancer 1998;77:1696–1703.

139. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998;77:2246–2251.

140. Takahashi Y, Bucana CD, Akagi Y, Liu W, Cleary KR, Mai M, Ellis LM. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 1998;4:429–434.

141. Aikawa H, Takahashi H, Fujimura S, Sato M, Endo C, Sakurada A, Kondo T, Tanita T, Matsumura Y, Ono S, Saito Y, Sagawa M. Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer. Anticancer Res 1999;19:4305–4309.

142. Saito S, Tsuno N, Nagawa H, Sunami E, Zhengxi J, Osada T, Kitayama J, Shibata Y, Tsuruo T, Muto T. Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer 2000;88:42–49.

143. Ueda M, Terai Y, Kumagai K, Ueki K, Okamoto Y, Ueki M. Correlation between tumor angiogenesis and expression of thymidine phosphorylase, and patient outcome in uterine cervical carcinoma. Hum Pathol 1999;30:1389–1394.

144. Matsuura T, Kuratate I, Teramachi K, Osaki M, Fukuda Y, Ito H. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas. Cancer Res 1999;59:5037–5040.

145. Saito H, Tsujitani S, Oka S, Kondo A, Ikekuchi M, Maeta M, Kaibara N. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer 1999;81:484–489.

146. Shomori K, Sakatani T, Goto A, Matsuura T, Kiyonari H, Ito H. Thymidine phosphorylase expression in human colorectal mucosa, adenoma and carcinoma: Role of p53 expression. Pathol Int 1999;49:491–499.

147. Ikeguchi M, Oka S, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N. Clinical significance of the detection of thymidine phosphorylase activity in esophageal squamous cell carcinomas. Eur Surg Res 1999;31:357–363.

148. Yamashita J, Ogawa M, Abe M, Nishida M. Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer. Chest 1999;116:206–211.

149. Kodama J, Yoshinouchi M, Seki N, Hongo A, Miyagi Y, Kudo T. Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer. Int J Oncol 1999;15:149–154.

150. Koide N, Watanabe H, Yazawa K, Adachi W, Amano J. Immunohistochemical expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in squamous cell carcinoma of the esophagus. Hepatogastroenterology 1999;46:944–951.

151. Toi M, Ueno T, Matsumoto H, Saji H, Funata N, Koike M, Tominaga T. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res 1999;5:1131–1137.

152. Hata K, Takebayashi Y, Iida K, Fujiwaki R, Fukumoto M, Miyazaki K. Expression of thymidine phosphorylase in human cervical cancer. Anticancer Res 1999;19:709–716.

153. Volm M, Koomagi R, Mattern J. PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 1999;19:651–655.
154. Hata K, Kamikawa T, Arai S, Tashiro H, Katabuchi H, Okamura H, Fujiwaki R, Miyazaki K, Fukumoto M. Expression of the thymidine phosphorylase gene in epithelial ovarian cancer. Br J Cancer 1999;79:1848–1854.

155. Tanioka K, Takeshima H, Hirano H, Kimura T, Nagata S, Akiyama S, Kuratsu J. Biological role of thymidine phosphorylase in human astrocytic tumors. Oncol Rep 2001;8:491–496.

156. Hata K, Fujiwaki R, Nakayama K, Maede Y, Fukumoto M, Miyazaki K. Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: Correlation with angiogenesis and progression of the tumor. Anticancer Res 2000;20:3941–3949.

157. Okada K, Yokoyama K, Okihara K, Ukimura O, Kojima M, Miki T, Takamatsu T. Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate. Urology 2001;57:376–381.

158. Matsumoto Y, Ishiko O, Deguchi M, Ogita S, Haba T, Wakasa K. Platelet-derived endothelial cell growth factor in keratinizing-type squamous cell uterine cervical cancer. Oncol Rep 2001;8:93–97.

159. Tera Y, Ueda M, Kumagai K, Ueki K, Ueki M. Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum. Int J Gynecol Pathol 2000;19:354–360.

160. Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. J Clin Oncol 2000;18:3946–3951.

161. Dobbs SP, Brown LJ, Ireland D, Abrams KR, Murray JC, Gatter K, Harris A, Steward WP, O’Byrne KJ. Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Ann Diagn Pathol 2000;4:286–292.

162. Li Z, Shimada Y, Uchida S, Maeda M, Kawabe A, Mori A, Itami A, Kano M, Watanabe G, Imamura M. TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000;17:453–460.

163. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T. The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers. Cancer Res 2000;60:3662–3665.

164. Sakatani T, Okamoto E, Tsujitani S, Ikeguchi M, Kaibara N, Ito H. Expressions of thymidine phosphorylase (dThdPase) and vascular endothelial growth factor on angiogenesis in intestinal-type gastric carcinoma. Oncol Rep 2000;7:831–836.

165. Takano S, Tsuboi K, Matsumura A, Tomono Y, Mitsui Y, Nose T. Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors. J Cancer Res Clin Oncol 2000;126:145–152.

166. Van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Boitsma HF, Peters GJ. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000;6:1063–1072.

167. Tang W, Wang X, Utsunomiya H, Nakamuta Y, Yang Q, Zhang Q, Zhou G, Tsubota Y, Mabuchi Y, Li L, Nakudo K. Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: Histological features and microvessel density. Cancer Lett 2000;148:153–159.

168. Tanaka T, Yoshiki T, Arai Y, Higuchi K, Kageyama S, Ogawa Y, Isono T, Okada Y. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human bladder cancer. Jpn J Cancer Res 1999;90:1344–1350.

169. Fujiwaki R, Hata K, Iida K, Maede Y, Koike M, Miyazaki K. Thymidine phosphorylase expression in progression of cervical cancer: Correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis. J Clin Pathol 1999;52:598–603.

170. Hirohara Y, Takayama T, Kageyama S, Ushiyama T, Suzuki K, Fujita K. Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: Relationship between histological parameters and chemosensitivity to 5-fluorouracil. Eur Urol 2003;43:45–51.
171. Hirano Y, Kageyama S, Ushiyama T, Suzuki K, Fujita K. Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer. Cancer Chemother Pharmacol 2003;51:29–35.

172. Kaio E, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, Chayama K. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2003;64:61–73.

173. Ranieri G, Labriola A, Achille G, Florio G, Zito AF, Grammatica L, Paradiso A. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. Int J Onmol 2002;21:1317–1323.

174. Aoki T, Katsumata K, Tsuchida A, Tomioha K, Koyanagi Y. Correlation between malignancy grade and p53 gene in relation to thymidine phosphorylase activity in colorectal cancer patients. Oncol Rep 2002;9:1267–1271.

175. Yao L, Itoh S, Furuta I. Thymidine phosphorylase expression in oral squamous cell carcinoma. Oral Oncol 2002;38:584–590.

176. Kanzaki A, Takebayashi Y, Bando H, Eliaison JF, Watanabe SS, Miyashita H, Fukumoto M, Toi M, Uchida T. Expression of uridine and thymidine phosphorylase genes in human breast carcinoma. Int J Cancer 2002;97:631–635.

177. Yang Q, Barbareschi M, Mori I, Mauri F, Muscarra M, Nakamura M, Nakamura Y, Yoshimura G, Sakurai T, Caffo O, Galligioni E, Dalla PP, Kakudo K. Prognostic value of thymidine phosphorylase expression in breast carcinoma. Int J Cancer 2002;97:512–517.

178. Yao Y, Kubota T, Sato K, Kitai R. Macrophage infiltration-associated thymidine phosphorylase expression correlates with increased microvessel density and poor prognosis in astrocytic tumors. Clin Cancer Res 2001;7:4021–4026.

179. Makoto O, Takeda A, Ting-Leig L, Shinnichi O, Hisahiro M, Yutaka F, Yoshihiro N, Kobayashi S, Gunji Y, Suzuki T, Takenori O, Hideaki S. Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma. Oncol Rep 2002;9:23–28.

180. Yano T, Takeo S. Thymidine phosphorylase expression in non-small cell lung carcinoma tissues. Cancer 2001;92:2658–2661.

181. Li S, Nomata K, Sawase K, Noguchi M, Kanda S, Kanetake H. Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer. Int J Urol 2001;8:478–482.

182. Hirano H, Tanioka K, Yokoyama S, Akiyama S, Kuratsu J. Angiogenic effect of thymidine phosphorylase on macrophages in glioblastoma multiforme. J Neurosurg 2001;95:89–95.

183. van Halteren HK, Peters HM, van Krieken JH, Coebergh JW, Roumen RM, van der WE, Wagener JT, Vreugdenhil G. Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Aster Coller B1/B2 colorectal carcinoma. Cancer 2001;91:1752–1757.

184. Okamoto E, Osaki M, Kase S, Adachi H, Kaibara N, Ito H. Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas. Pathol Int 2001;51:158–164.

185. Suzuki K, Morita T, Hashimoto S, Tokue A. Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma. Urol Res 2001;29:7–12.

186. Ioachim E. Thymidine phosphorylase expression in breast cancer: The prognostic significance and its association with other angiogenesis related proteins and extracellular matrix components. Histol Histopathol 2008;23:187–196.

187. Kobayashi Y, Wada Y, Ohara T, Okuda Y, Suzuki N, Hasegawa K, Kiguchi K, Ishizuka B. Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues. Hum Cell 2007;20:107–110.

188. Nonomura N, Nakai Y, Nakayama M, Inoue N, Nishimura K, Hatanaka E, Arima R, Kishimoto T, Miki T, Kuroda H, Okuyama A. The expression of thymidine phosphorylase is a
prognostic predictor for the intravesical recurrence of superficial bladder cancer. Int J Clin Oncol 2006;11:297–302.

189. Takayama T, Mugiya S, Sugiyama T, Aoki T, Furuse H, Liu H, Hirano Y, Kai F, Ushiyama T, Ozono S. High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma. Jpn J Clin Oncol 2006;36:564–569.

190. Aoki S, Yamada Y, Nakamura K, Taki T, Tobiume M, Honda N. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer. Oncol Rep 2006;16:279–284.

191. Nomita Y, Nemoto K, Nakata E, Takai Y, Yamada S. Expression of thymidine phosphorylase and VEGF in esophageal squamous cell carcinoma. Oncol Rep 2006;15:1497–1501.

192. Lassmann S, Hennig M, Rosenberg R, Nahrig J, Schreglmann J, Krause F, Poignee-Heger M, Nekarda H, Hofler H, Werner M. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis 2006;21:238–247.

193. Stavropoulos NE, Bouropoulos C, Ioachim E, Michael M, Hastazeris K, Tsimaris I, Kalogeras D, Lianis Z, Kafarakis V, Stefanaki S, Maranou-Mitsi V. Prognostic significance of thymidine phosphorylase expression in superficial bladder carcinoma. Oncol Rep 2006;15:559–565.

194. Li C, Shintani S, Terakado N, Klosek SK, Ishikawa T, Nakashiro H, Hamakawa H. Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas. Int J Oral Maxillofac Surg 2005;34:559–565.

195. Kataoka A, Yuasa T, Kageyama S, Iwaki H, Higuchi K, Tanaka T, Okada Y, Yoshiki T. Expression of thymidine phosphorylase correlates with microvessel density in prostate cancer. Oncol Rep 2005;13:597–600.

196. Yasuno M, Mori T, Koike M, Takahashi K, Toi M, Takizawa T, Shimizu S, Yamaguchi T, Matsumoto H. Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. Oncol Rep 2005;13:405–412.

197. Mizutani Y, Wada H, Yoshida O, Fukushima M, Kawauchi A, Nakao M, Miki T. The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer. Cancer Lett 2003;200:173–176.

198. Morita T, Matsuzaki A, Tokue A. Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma. Oncology 2003;65:125–131.

199. Sato J, Sata M, Nakamura H, Inoue S, Wada T, Takabatake N, Otake K, Tomoike H, Kubota I. Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma. Int J Cancer 2003;106:863–870.

200. Mizutani Y, Wada H, Yoshida O, Fukushima M, Kawauchi A, Nakao M, Miki T. The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in renal cell carcinoma. Cancer 2003;98:730–736.

201. Kikuno N, Yoshino T, Utakami S, Shigeno K, Kishi H, Hata K, Shiina H, Igawa M. The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer. Anticancer Res 2003;23:1305–1312.

202. Wada S, Yoshimura R, Naganuma T, Yoshida N, Narita K, Ikemoto S. Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma. BJU Int 2003;91:105–108.
206. Morita T, Matsuzaki A, Suzuki K, Tokue A. Role of thymidine phosphorylase in biomodulation of fluoropyrimidines. Curr Pharm Biotechnol 2001;2:257–267.

207. Ono M. Molecular links between tumor angiogenesis and inflammation: Inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008;99:1501–1506.

208. Torisu-Itakura H, Furue M, Kuwano M, Ono M. Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas. Jpn J Cancer Res 2000;91:906–910.

209. Zhang JM, Mizoi T, Shiiba K, Sasaki I, Matsuno S. Expression of thymidine phosphorylase by macrophages in colorectal cancer tissues. World J Gastroenterol 2004;10:545–549.

210. Sivridis E, Giatromanolaki A, Papadopoulos I, Gatter KC, Harris AL, Koukourakis MI. Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: Correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis. Br J Cancer 2002;86:1465–1471.

211. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207–1225.

212. Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya Y, Hayashi H, Takeda A, Shiratori T, Uno T, Ito H, Ochiai T. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002;86:552–557.

213. Pauly JL, Schuller MG, Zeleer AA, Kirss TA, Gore SS, Germain MJ. Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients. J Natl Cancer Inst 1977;58:1587–1590.

214. Pauly JL, Paolini NS, Ebarb RL, Germain MJ. Elevated thymidine phosphorylase activity in the plasma and ascites fluids of tumor-bearing animals. Proc Soc Exp Biol Med 1978;157:262–267.

215. Shimada H, Takeda A, Shiratori T, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Hayashi H, Gunji Y, Kobayashi S, Suzuki T, Ochiai T. Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma. Cancer 2002;94:1947–1954.

216. Haraguchi M, Komuta K, Akashi A, Furui J, Kanematsu T. Occurrence of hematogenous metastasis and serum levels of thymidine phosphorylase in colorectal cancer. Oncol Rep 2003;10:1207–1212.

217. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967–974.

218. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932–936.

219. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273–286.

220. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401–410.

221. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K, Akiyama S, Yamada Y. Angiogenic activity of enzymes. Nature 1994;368:198.

222. Liekens S, Bilsen F, De Clercq E, Priego EM, Camarusa MJ, Pérez-Pérez MJ, Balzarini J. Anti-angiogenic activity of a novel multi-substrate analogue inhibitor of thymidine phosphorylase. FEBS Lett 2002;510:83–88.

223. Uchimiya H, Furukawa T, Okamoto M, Nakajima Y, Matsushita S, Ikeda R, Gotanda T, Haraguchi M, Sumizawa T, Ono M, Kuwano M, Kanzaki T, Akiyama S. Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-β-ribose. Cancer Res 2002;62:2834–2839.

224. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, Akiyama S. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 1995;55:1687–1690.

225. Pula G, Mayr U, Evans C, Prokop M, Vara DS, Yin X, Astrolakis Z, Xiao Q, Hill J, Xu Q, Mayr M. Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures. Circ Res 2009;104:32–40.
226. Asahara T, Murohara T, Sullivan A, Silver M, van der ZR, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.

227. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221–228.

228. Marsboom G, Janssens S. Endothelial progenitor cells: New perspectives and applications in cardiovascular therapies. Expert Rev Cardiovasc Ther 2008;6:687–701.

229. Debatin KM, Wei J, Beltinger C. Endothelial progenitor cells for cancer gene therapy. Gene Ther 2008;15:780–786.

230. Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res 2003;63:527–533.

231. Sengupta S, Sellers LA, Matheson HB, Fan TP. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: An evaluation of possible mechanisms. Br J Pharmacol 2003;139:219–231.

232. Stevenson DP, Milligan SR, Collins WP. Effects of platelet-derived endothelial cell growth factor/thymidine phosphorylase, substrate, and products in a three-dimensional model of angiogenesis. Am J Pathol 1998;152:1641–1646.

233. Stevenson DP, Collins WP, Farzaneh F, Hata K, Miyazaki K. Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: Implications for the treatment of ovarian cancer. Am J Pathol 1998;153:1573–1578.

234. Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000;60:6298–6302.

235. de Bruin M, Smid K, Laan AC, Noordhuis P, Fukushima M, Hoekman K, Pinedo HM, Peters GJ. Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem Biophys Res Commun 2003;301:675–679.

236. Usuki K, Miyazono K, Heldin CH. Covalent linkage between nucleotides and platelet-derived endothelial cell growth factor. J Biol Chem 1991;266:20525–20531.

237. Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998;334:1–8.

238. Groarke JM, Mahoney WC, Hope JN, Furlong CE, Robb FT, Zalkin H, Hermodson MA. The amino acid sequence of D-ribose-binding protein from Escherichia coli K12. J Biol Chem 1983;258:12952–12956.

239. Usuki K, Miyazono K, Heldin CH. Thymidine phosphorylase and 2-deoxy-D-ribose in angiogenesis. Biochem J 1998;334:1–8.

240. Groarke JM, Mahoney WC, Hope JN, Furlong CE, Robb FT, Zalkin H, Hermodson MA. The amino acid sequence of D-ribose-binding protein from Escherichia coli K12. J Biol Chem 1983;258:12952–12956.

241. Wolanin PM, Thomason PA, Stock JB. Histidine protein kinases: Key signal transducers outside the animal kingdom. Genome Biol 2002;3:REVIEWS3013.

242. Hotchkiss KA, Ashton AW, Schwartz EL. Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. J Biol Chem 2003;278:19272–19279.

243. Seeliger H, Guba M, Koehl GE, Doenecke A, Steinbauer M, Bruns CJ, Wagner C, Frank E, Jauch KW, Geissler EK. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 2004;10:1843–1852.

244. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mTOR in solid tumor systems: A therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007;26:611–621.

245. Malik RK, Parsons JT. Integrin-dependent activation of the p70 ribosomal S6 kinase signaling pathway. J Biol Chem 1996;271:29785–29791.

246. Gan B, Yoo Y, Guan JL. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of S6 kinase activation and cell growth. J Biol Chem 2006;281:37321–37329.
245. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 1969;244:6388–6394.

246. Bussolati B, Ahmed A, Pemberton H, Landis RC, Di Carlo F, Haskard DO, Mason JC. Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: Induction of angiogenesis and inhibition of leukocytic infiltration. Blood 2004;103:761–766.

247. Deshane J, Chen S, Caballero S, Grochot-Przeczek A, Was H, Li CS, Lach R, Hock TD, Chen B, Hill-Kapturczak N, Siegal GP, Dulak J, Jozkowicz A, Grant MB, Agarwal A. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J Exp Med 2007;204:605–618.

248. Loboda A, Jazwa A, Grochot-Przeczek A, Rutkowski AJ, Cisowski J, Agarwal A, Jozkowicz A, Dulak J. Heme oxygenase-1 and the vascular bed: From molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2008;10:1767–1812.

249. Dulak J, Deshane J, Jozkowicz A, Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: Focus on angiogenesis. Circulation 2008;117:231–241.

250. Deramaudt BM, Braunstein S, Remy P, Abraham NG. Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. J Cell Biochem 1998;68:121–127.

251. Jazwa A, Loboda A, Golda S, Cisowski J, Szelag M, Zagorska A, Sroczynska P, Drukala J, Jozkowicz A, Dulak J. Effect of heme and heme oxygenase-1 on vascular endothelial growth factor synthesis and angiogenic potency of human keratinocytes. Free Radic Biol Med 2006;40:1250–1263.

252. Li W, Tanaka K, Morioka K, Uesaka T, Yamada N, Takamori A, Handa M, Tanabe S, Ihaya A. Thymidine phosphorylase gene transfer inhibits vascular smooth muscle cell proliferation by upregulating heme oxygenase-1 and p27KIP1. Arterioscler Thromb Vasc Biol 2005;25:1370–1375.

253. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69:4–10.

254. Brown NS, Streeter EH, Jones A, Harris AL, Bicknell R. Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: The effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. Br J Cancer 2005;92:1696–1701.

255. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480–498.

256. Ueda M, Terai Y, Kumagai K, Ueki K, Kanemura M, Ueki M. Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells. Int J Cancer 2001;91:778–782.

257. Nakajima Y, Haraguchi M, Furukawa T, Yamamoto M, Nakanishi H, Tatematsu M, Akiyama S. 2-Deoxy-β-ribose inhibits the invasion of thymidine phosphorylase-overexpressing tumors by suppressing matrix metalloproteinase-9. Int J Cancer 2006;119:1710–1716.

258. Gotanda T, Haraguchi M, Tachiwada T, Shinkura R, Koriyama C, Akiba S, Kawahara M, Nishiyama K, Sumizawa T, Furukawa T, Mimata H, Nomura Y, Akiyama S, Nakagawa M. Molecular basis for the involvement of thymidine phosphorylase in cancer invasion. Int J Mol Med 2006;17:1085–1091.

259. Kurizaki T, Toi M, Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep 1998;5:673–677.

260. Gunningham SP, Currie MJ, Morrin HR, Tan EY, Turley H, Dachs GU, Watson AI, Frampton C, Robinson BA, Fox SB. The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers. J Pathol 2007;212:335–344.

261. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001;98:3352–3357.
262. Morbidelli L, Brogelli L, Granger HJ, Ziche M. Endothelial cell migration is induced by soluble P-selectin. Life Sci 1998;62:L7–11.

263. Currie MJ, Gunningham SP, Han C, Scott PA, Robinson BA, Harris AL, Fox SB. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin Cancer Res 2001;7:918–927.

264. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonnier PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161–1169.

265. Papapetropoulos A, Garcia-Cardenas G, Dengler TJ, Maisonnier PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: Evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999;79:213–223.

266. Suri C, Jones PF, Patan S, Bartunkova S, Maisonnier PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171–1180.

267. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 1999;448:249–253.

268. Li W, Tanaka K, Ihaya A, Fujibayashi Y, Takamatsu S, Morioka K, Sasaki M, Uesaka T, Kimura T, Yamada N, Tsuda T, Chiba Y. Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs. Am J Physiol Heart Circ Physiol 2005;288:H408–H415.

269. Li W, Tanaka K, Morioka K, Takamori A, Handa M, Yamada N, Ihaya A. Long-term effect of gene therapy for chronic ischemic myocardium using platelet-derived endothelial cell growth factor in dogs. J Gene Med 2008;10:412–420.

270. Deng YM, Wu BJ, Witting PK, Stocker R. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation 2004;110:1855–1860.

271. Handa M, Li W, Morioka K, Takamori A, Yamada N, Ihaya A. Adventitial delivery of platelet-derived endothelial cell growth factor gene prevented intimal hyperplasia of vein graft. J Vasc Surg 2008;48:1566–1574.

272. Takao S, Akiyama SI, Nakajo A, Yoh H, Kitazono M, Natsugoe S, Miyadera K, Fukushima M, Yamada Y, Aikou T. Suppression of metastasis by thymidine phosphorylase inhibitor. Cancer Res 2000;60:5345–5348.

273. Nakajima Y, Gotanda T, Uchimiy H, Furukawa T, Haraguchi M, Ikeda R, Sumizawa T, Yoshida H, Akiyama S. Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose. Cancer Res 2004;64:1794–1801.

274. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000;60:4932–4938.

275. Matsushita S, Nitanda T, Furukawa T, Sumizawa T, Tani A, Nishimoto K, Akiba S, Miyadera K, Fukushima M, Yamada Y, Yoshida H, Kanzaki T, Akiyama S. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res 1999;59:1911–1916.

276. Ikeguchi M, Cai J, Fukuda K, Oka S, Katano K, Tsujitani S, Maeta M, Kaibara N. Correlation between spontaneous apoptosis and the expression of angiogenic factors in advanced gastric adenocarcinoma. J Exp Clin Cancer Res 2001;20:257–263.

277. Hata K, Fujiwaki R, Maede Y, Nakayama K, Fukushima M, Miyazaki K. Expression of thymidine phosphorylase in epithelial ovarian cancer: Correlation with angiogenesis, apoptosis, and ultrasound-derived peak systolic velocity. Gynecol Oncol 2000;77:26–34.

278. Kitazono M, Takebayashi Y, Ishitsuka K, Takao S, Tani A, Furukawa T, Miyadera K, Yamada Y, Aikou T, Akiyama S. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 1998;253:797–803.

Medicinal Research Reviews DOI 10.1002/med
279. Ikeda R, Furukawa T, Kitazono M, Ishitsuka K, Okumura H, Tani A, Sumizawa T, Haraguchi M, Komatsu M, Uchimiya H, Ren QX, Motoya T, Yamada K, Akiyama S. Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose. Biochem Biophys Res Commun 2002;291:806–812.

280. Ikeda R, Che XF, Ushiyama M, Yamaguchi T, Okumura H, Nakajima Y, Takeda Y, Shibayama Y, Furukawa T, Yamamoto M, Haraguchi M, Sumizawa T, Yamada K, Akiyama S. 2-Deoxy-D-ribose inhibits hypoxia-induced apoptosis by suppressing the phosphorylation of p38 MAPK. Biochem Biophys Res Commun 2006;342:280–285.

281. Ikeda R, Tajitsu Y, Iwashita K, Che XF, Yoshida K, Ushiyama M, Furukawa T, Komatsu M, Yamaguchi T, Shibayama Y, Yamamoto M, Zhao HY, Arima J, Takeda Y, Akiyama S, Yamada K. Thymidine phosphorylase inhibits the expression of proapoptotic protein BNIP3. Biochem Biophys Res Commun 2008;370:220–224.

282. Ikeda R, Furukawa T, Mitsuo R, Noguchi T, Kitazono M, Okumura H, Sumizawa T, Haraguchi M, Che XF, Uchimiya H, Nakajima Y, Ren QX, Oiso S, Inoue I, Yamada K, Akiyama S. Thymidine phosphorylase inhibits apoptosis induced by cisplatin. Biochem Biophys Res Commun 2003;301:358–363.

283. Jeung HC, Che XF, Haraguchi M, Furukawa T, Zheng CL, Sumizawa T, Rha SY, Roh JK, Akiyama S. Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Biochem Pharmacol 2005;70:13–21.

284. Jeung HC, Che XF, Haraguchi M, Zhao HY, Furukawa T, Gotanda T, Zheng CL, Tsuneyoshi K, Sumizawa T, Roh JK, Akiyama S. Protection against DNA damage-induced apoptosis by the angiogenic factor thymidine phosphorylase. FEBS Lett 2006;580:1294–1302.

285. Mori S, Takao S, Ikeda R, Noma H, Mataki Y, Wang X, Akiyama S, Aiko T. Role of thymidine phosphorylase in Fas-induced apoptosis. Hum Cell 2001;14:323–330.

286. Mori S, Takao S, Ikeda R, Noma H, Mataki Y, Wang X, Akiyama S, Aikou T. Thymidine phosphorylase suppresses Fas-induced apoptotic signal transduction independent of its enzymatic activity. Biochem Biophys Res Commun 2002;295:300–305.

287. Stenman G, Sahlin P, Dumanski JP, Hagiwara K, Ishikawa F, Miyazono K, Collins VP, Heldin CH. Regional localization of the human platelet-derived endothelial cell growth factor (ECGF1) gene to chromosome 22q13. Cytogenet Cell Genet 1992;59:22–23.

288. Hagiwara K, Stenman G, Honda H, Sahlin P, Andersson A, Miyazono K, Heldin CH, Ishikawa F, Takaku F. Organization and chromosomal localization of the human platelet-derived endothelial cell growth factor gene. Mol Cell Biol 1991;11:2125–2132.

289. Zhu GH, Lenzi M, Schwartz EL. The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells. Oncogene 2002;21:8477–8485.

290. Rohlff C, Ahmad S, Borellini F, Lei J, Glazer RI. Modulation of transcription factor Sp1 by cAMP-dependent protein kinase. J Biol Chem 1997;272:21137–21141.

291. Finkenzeller G, Sparacio A, Technau A, Marme D, Siemeister G. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 1997;15:669–676.

292. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1995;1:961–964.

293. Amaya H, Tanigawa N, Lu C, Matsumura M, Shimomatsuya T, Horiiuchi T, Muraoka R. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 1997;119:227–235.

294. Fukuiwa T, Takebayashi Y, Akiba S, Matsuoka T, Hanamure Y, Miyadera K, Yamada Y, Akiyama S. Expression of thymidine phosphorylase and vascular endothelial cell growth factor in...
human head and neck squamous cell carcinoma and their different characteristics. Cancer 1999;85:960–969.

295. Kojima H, Shijubo N, Abe S. Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. Cancer 2002;94:1083–1093.

296. Fujiwaki R, Hata K, Iida K, Maede Y, Miyazaki K. Vascular endothelial growth factor expression in progression of cervical cancer: Correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis. Anticancer Res 2000;20:1317–1322.

297. Harino Y, Imura S, Kanemura H, Morine Y, Fujii M, Ikegami T, Uehara H, Shimada M. Role of tumor angiogenesis in gallbladder carcinoma: With special reference to thymidine phosphorylase. Int J Clin Oncol 2008;13:452–457.

298. O’Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995;55:510–513.

299. Schwartz EL, Wan E, Wang FS, Baptiste N. Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells. Cancer Res 1998;58:1551–1557.

300. Goto H, Kohno K, Sone S, Akiyama S, Kuwano M, Ono M. Interferon gamma-dependent induction of thymidine phosphorylase/platelet-derived endothelial growth factor through gamma-activated sequence-like element in human macrophages. Cancer Res 2001;61:469–473.

301. Yao Y, Kubota T, Sato K, Takeuchi H, Kitai R, Matsukawa S. Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells. J Neurooncol 2005;72:217–223.

302. Fukushima M, Okabe H, Takechi T, Ichikawa W, Hirayama R. Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity. Cancer Lett 2002;187:103–110.

303. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, Ishitsuka H. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993;32:333–338.

304. Zhu GH, Schwartz EL. Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: Induction by autocrine tumor necrosis factor-alpha and inhibition by aspirin. Mol Pharmacol 2003;64:1251–1258.

305. de Bruin M, Peters GJ, Oerlemans R, Assaraf YG, Masterson AJ, Adema AD, Dijkmans BA, Pinedo HM, Jansen G. Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells. Mol Pharmacol 2004;66:1054–1060.

306. Kusabe T, Waguri-Nagaya Y, Tanikawa T, Aoyama M, Fukuoka M, Kobayashi M, Otsuka T, Asai K. The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on glosstatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes. Rheumatol Int 2005;25:625–630.

307. Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther 2002;1:1139–1145.

308. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013–1019.

309. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999;5:2948–2953.

310. Guarcello V, Blanquicett C, Naguib FN, El Kouni MH. Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity. Cancer Chemother Pharmacol 2008;62:85–96.

Medicinal Research Reviews DOI 10.1002/med
311. Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 1997;57:570–572.

312. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182–1186.

313. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592–603.

314. Fernando NT, Koch M, Rothrock C, Gollogly LK, D’Amore PA, Ryeom S, Yoon SS. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008;14:1529–1539.

315. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83–95.

316. Pérez-Pérez MJ, Priego EM, Hernandez AI, Camarasa MJ, Balzarini J, Liekens S. Thymidine phosphorylase inhibitors: Recent developments and potential therapeutic applications. Mini Rev Med Chem 2005;5:1113–1123.

317. Langen P, Ettzold G, Barwolff D, Preussel B. Inhibition of thymidine phosphorylase by 6-aminothymine and derivatives of 6-aminouracil. Biochem Pharmacol 1967;16:1833–1837.

318. Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, Yamada Y, Asao T. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. Biochem Pharmacol 2000;59:1227–1236.

319. Balzarini J, Gamboa AE, Esnouf R, Liekens S, Neyts J, De Clercq E, Camarasa MJ, Pérez-Pérez MJ. 7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase. FEBS Lett 1998;438:91–95.

320. Balzarini J, Degreve B, Esteban-Gamboa A, Esnouf R, De Clercq E, Engelborghs Y, Camarasa MJ, Pérez-Pérez MJ. Kinetic analysis of novel multisubstrate analogue inhibitors of thymidine phosphorylase. FEBS Lett 2000;483:181–185.

321. Esteban-Gamboa A, Balzarini J, Esnouf R, De Clercq E, Camarasa MJ, Pérez-Pérez MJ. Design, synthesis, and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylase. J Med Chem 2000;43:971–983.

322. Liekens S, Hernandez AI, Ribatti D, De Clercq E, Camarasa MJ, Pérez-Pérez MJ, Balzarini J. The nucleoside derivative 5'-O-trityl-inosine (KIN59) suppresses thymidine phosphorylase-triggered angiogenesis via a noncompetitive mechanism of action. J Biol Chem 2004;279:29598–29605.

323. Liekens S, Bronckaers A, Hernandez AI, Priego EM, Casanova E, Camarasa MJ, Pérez-Pérez MJ, Balzarini J. 5'-O-tritylated nucleoside derivatives: Inhibition of thymidine phosphorylase and angiogenesis. Mol Pharmacol 2006;70:501–509.

324. Cole C, Reigan P, Gbaj A, Edwards PN, Douglas KT, Stratford IJ, Freeman S, Jaffar M. Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: Inhibitors of the angiogenic enzyme thymidine phosphorylase. J Med Chem 2003;46:207–209.

325. Reigan P, Edwards PN, Gbaj A, Cole C, Barry ST, Page KM, Ashton SE, Luke RW, Douglas KT, Stratford IJ, Jaffar M, Bryce RA, Freeman S. Aminimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs. J Med Chem 2005;48:392–402.

326. Reigan P, Gbaj A, Stratford IJ, Bryce RA, Freeman S. Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors. Eur J Med Chem 2008;43:1248–1260.

327. Heidelberger C, Chaudhuri N, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer R, Pleven E, Scheiner J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957;179:663–666.
328. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330–338.

329. Peters GJ, Laurense E, Leyva A, Pinedo HM. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer Clin Oncol 1987;23:1869–1881.

330. Schwartz EL, Baptiste N, O'Connor CJ, Wadler S, Otter BA. Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase. Cancer Res 1994;54:1472–1478.

331. Ciccolini J, Cuq P, Evrard A, Giacometti S, Pelegrin A, Aubert C, Cano JP, Iliadis A. Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Mol Cancer Ther 2001;1:133–139.

332. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974;13:471–481.

333. Sommer H, Santi DV. Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2'-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun 1974;57:689–695.

334. Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C, Lastella M, Federici F, Iannopollo M, Falcone A, Ricci S, Del Tacca M, Danesi R. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res 2008;14:2749–2755.

335. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced colorectal cancer meta-analysis project. J Clin Oncol 1992;10:896–903.

336. Douillard JY, Bennouna J, Senellart H. Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? Clin Colorectal Cancer 2008;7:206–211.

337. Takechi T, Nakano K, Uchida J, Mitia A, Toko K, Takeda S, Unemi N, Shirasaka T. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997;39:205–211.

338. Kanamitsu SI, Ito K, Okuda H, Ogura K, Watabe T, Muro K, Sugiyama Y. Prediction of in vivo drug–drug interactions based on mechanism-based inhibition from in vitro data: Inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil. Drug Metab Dispos 2000;28:467–474.

339. Ogura K, Nishiyama T, Takubo H, Kato A, Okuda H, Arakawa K, Fukushima M, Nagayama S, Kawaguchi Y, Watabe T. Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett 1998;122:107–113.

340. Porter DJ, Chestnut WG, Merrill BM, Spector T. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 1992;267:5236–5242.

341. Heslin MJ, Yan J, Weiss H, Shao L, Owens J, Lucas VS, Diasio RB. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. Cancer Chemother Pharmacol 2003;52:399–404.

342. Hoff PM. Practical considerations in the use of oral fluoropyrimidines. Semin Oncol 2003;30:88–92.

343. Sugata S, Kono A, Hara Y, Karube Y, Matsushima Y. Partial purification of a thymidine phosphorylase from human gastric cancer. Chem Pharm Bull (Tokyo) 1986;34:1219–1222.

344. de Bruin M, van Capel T, van der BK, Kruyt FA, Fukushima M, Hoekman K, Pinedo HM, Peters GJ. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 2003;88:957–964.

345. Yu LJ, Matias J, Scudiero DA, Hite KM, Monks A, Sausville EA, Waxman DJ. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 2001;29:304–312.

Medicinal Research Reviews DOI 10.1002/med
346. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos 2000;28:1457–1463.

347. Yoshisue K, Masuda H, Matsushima E, Ikeda K, Nagayama S, Kawaguchi Y. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab Dispos 2000;28:1162–1167.

348. Poorter RL, Bakker PJ, Veenhof CH. Continuous infusion of chemotherapy: Focus on 5-fluorouracil and fluorodeoxyuridine. Pharm World Sci 1998;20:45–59.

349. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: The end of an era? J Clin Oncol 2007;25:5649–5654.

350. Patterson AV, Zhang H, Moghaddam A, Bicknell R, Talbot DC, Stratford JJ, Harris AL. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 1995;72:669–675.

351. Kato Y, Matsukawa S, Muraoka R, Tanigawa N. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br J Cancer 1997;75:506–511.

352. Haraguchi M, Furukawa T, Sumizawa T, Akiyama S. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res 1993;53:5680–5682.

353. Evrard A, Cuq P, Robert B, Vian L, Pelegrin A, Cano JP. Enhancement of 5-fluorouracil cytotoxicity by human thymidine phosphorylases expression in cancer cells: In vitro and in vivo study. Int J Cancer 1999;80:465–470.

354. Bajetta E, Colleoni M, Rosso R, Sovero A, Amadori D, Comella G, Marangolo M, Scanni A, Lorusso V, Calabresi F. Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. Eur J Cancer 1993;29A:1658–1663.

355. Bollag W, Hartmann HR. Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine. Eur J Cancer 1980;16:427–432.

356. Temmink OH, de Bruin M, Turkosma AW, Cricca S, Laan AC, Peters GJ. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. Int J Biochem Cell Biol 2007;39:565–575.

357. Cao D, Russell RL, Zhang D, Leffert JJ, Pizzorno G. Uridine phosphorylase (−/−) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 2002;62:2313–2317.

358. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291–297.

359. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097–4106.

360. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282–2292.

361. Lamberti C, Sauerbruch T, Glasmacher A. Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer. Cancer Treat Rev 2005;31:648–652.

Medicinal Research Reviews DOI 10.1002/med
362. Twelves C, Wong A, Nowacki MP, Abt M, Burris III H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Kindler H, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696–2704.

363. Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: Underlying rationale and results of clinical trials. Oncologist 2007;12:375–389.

364. Dal Lago L, D’Hondt V, Awada A. Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors. Oncologist 2008;13:845–858.

365. Camidge DR, Gail ES, Gore L, O’Bryant CL, Leong SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs 2008;19:77–84.

366. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006;24:4069–4077.

367. Han JY, Hong EK, Lee SY, Yoon SM, Lee DH, Lee JS. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. J Clin Pathol 2005;58:650–654.

368. Honda J, Sasa M, Moriya T, Bando Y, Hirose T, Takahashi M, Nagao T, Tangoku A. Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-predictive results. J Med Invest 2008;55:54–60.

369. Koizumi W, Okayasu I, Hyodo I, Sakamoto J, Kojima H. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydopyrimidine dehydrogenase. Anticancer Drugs 2008;19:819–824.

370. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20:2812–2823.

371. Comella P, Casaretti R, Sandremenico C, Avallone A, Franco L. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: A review of the evidence. Drugs 2008;68:949–961.

372. Heidelberger C, Parsons D, Remy D. Syntheses of 5-trifluoromethyluracil and 5-trifluoromethyl-2’-deoxyuridine. J Med Chem 1964;7:1–5.

373. Reyes P, Heidelberger C. Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: Its mechanism of action and inhibition by fluorinated nucleotides. Mol Pharmacol 1965;1:14–30.

374. Eckstein JW, Foster PG, Finer-Moore J, Wataya Y, Santi DV. Mechanism-based inhibition of thymidylate synthase by 5-trithionomethyl)-2’-deoxyuridine 5’-monophosphate. Biochemistry 1994;33:15086–15094.

375. Emura T, Suzuki N, Yamaguchi M, Ohshima H, Fukushima M. A novel combination antitumor agent, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTC incorporation in DNA. Int J Oncol 2004;25:571–578.

376. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004;30:115–133.

377. Ansfield FJ, Ramirez G. Phase I and II studies of 2’-deoxy-5-(trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep 1971;55:205–208.

378. Dexter DL, Wolberg WH, Ansfeld FJ, Nelson L, Heidelberger C. The clinical pharmacology of 5-trifluoromethyl-2’-deoxyuridine. Cancer Res 1972;32:247–253.

379. Emura T, Nakagawa F, Fujioka A, Ohshima H, Kitazato K. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Oncol Rep 2004;11:381–387.
380. Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 2004;13:545–549.

381. Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 2007;98:779–789.

382. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 2008;26:445–454.

383. Temmink OH, Hoebe EK, van der BK, Ackland SP, Fukushima M, Peters GJ. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 2007;96:231–240.

384. Neale GA, Mitchell A, Finch LR. Enzymes of pyrimidine deoxyribonucleotide metabolism in Mycoplasma mycoides subsp. mycoides. J Bacteriol 1983;156:1001–1005.

385. Tham TN, Ferris S, Kovacic R, Montagnier L, Blanchard A. Identification of Mycoplasma pirum genes involved in the salvage pathways for nucleosides. J Bacteriol 1993;175:5281–5285.

386. Razin S, Yoge D, Naot Y. Molecular biology and pathogenicity of Mycoplasmas. Microbiol Mol Biol Rev 1998;62:1094–1156.

387. Krause D, Yoge D, Naot Y. In: McElhaney RN, Finch LR, Baseman JB, editors. Mycoplasmas: Molecular biology and pathogenesis. Washington, DC: American Society for Microbiology; 1992.

388. Cimolai N. Do mycoplasmas cause human cancer? Can J Microbiol 2001;47:691–697.

389. Liekens S, Bronckaers A, Balzarini J. Purine and pyrimidine antimetabolite-based anti-cancer treatment may be significantly improved by selective suppression of mycoplasma-encoded catabolic enzymes during therapy. Lancet Oncol 2009; in press.

390. Kidder M, Chan PJ, Seraj IM, Patton WC, King A. Assessment of archived paraffin-embedded cervical condyloma tissues for mycoplasma-conserved DNA using sensitive PCR-ELISA. Gynecol Oncol 1998;71:254–257.

391. Hayflick L, Kopprowski H. Direct agar isolation of mycoplasmas from human leukaemic bone marrow. Nature 1965;205:713–714.

392. Chan PJ, Seraj IM, Kalugdan TH, King A. Prevalence of mycoplasma conserved DNA in malignant ovarian cancer detected using sensitive PCR-ELISA. Gynecol Oncol 1996;63:258–260.

393. Huang S, Li JY, Wu J, Meng L, Shou CC. Mycoplasmal infections and different human carcinomas. World J Gastroenterol 2001;7:266–269.

394. Feng SH, Tsai S, Rodriguez J, Lo SC. Mycoplasmal infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells. Mol Cell Biol 1999;19:7995–8002.

395. Zhang S, Tsai S, Wu TT, Li B, Shih JW, Lo SC. Mycoplasma fermentans infection promotes immortalization of human peripheral blood mononuclear cells in culture. Blood 2004;104:4252–4259.

396. Tsai S, Shih JW, Lo SC. Mycoplasmas and oncogenesis: Persistent infection and multistage malignant transformation. Proc Natl Acad Sci USA 1995;92:10197–10201.

397. Ketcham CM, Anai S, Reutzel R, Sheng S, Schuster SM, Brenes RB, Agbandje-McKenna M, McKenna R, Rosser CJ, Boehlein SK. p37 Induces tumor invasiveness. Mol Cancer Ther 2005;4:1031–1038.

398. Goodison S, Nakamura K, Iczkowski KA, Anai S, Boehlein SK, Rosser CJ. Exogenous mycoplasmal p37 protein alters gene expression, growth and morphology of prostate cancer cells. Cytogenet Genome Res 2007;118:204–213.

399. Gong M, Meng L, Jiang B, Zhang J, Yang H, Wu J, Shou C. p37 From Mycoplasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR. Mol Cancer Ther 2008;7:530–537.

Medicinal Research Reviews DOI 10.1002/med
Annelies Bronckaers obtained her degree of Master in biological sciences (2004) at the Katholieke Universiteit Leuven (K.U. Leuven), Belgium. She is currently a Ph.D. student at the K.U.Leuven since 2004. Her thesis research project is focused on the role of thymidine phosphorylase and thymidine phosphorylase inhibitors in angiogenesis.

Federico Gago studied pharmacy at Complutense University in Madrid and completed his Ph.D. in Alcalá University, near Madrid. After pursuing postdoctoral studies in Oxford University under the supervision of Prof. W. Graham Richards, he returned to Alcalá where he is currently an associate professor of Pharmacology. His research interests are in the areas of molecular modelling, drug design, structure-activity relationships, and computer simulations of biomolecular systems including DNA, enzymes, and pharmacological membrane receptors.

Jan Balzarini obtained his degree of Master in biological sciences (1975) and his degree of bio-engineering in biochemistry and microbiology (1977) at the Katholieke Universiteit Leuven (K.U.Leuven), Belgium. In 1984, he obtained his Ph.D. as Doctor in the bio-engineering at the Rega Institute for Medical Research, and received a tenured research position at the K.U.Leuven. After a postdoctoral stay at the National Institutes of Health, Jan Balzarini became, respectively, assistant-, associate-, and eventually full professor of Virology and Chemotherapy at the Faculty of Medicine of the K.U.Leuven. He currently acts as head of the Laboratory of Virology and Chemotherapy at the Rega Institute of the K.U.Leuven. His research projects are focussed on combined gene/chemotherapy of cancer, nucleoside kinases, antiviral chemotherapy (with a focus on HIV, influenza, and coronaviruses), mechanism of action of antiviral/anticancer drugs, and molecular mechanisms of antiviral drug resistance.

Sandra Liekens graduated in 1994 as a bio-engineer in chemistry at the Katholieke Universiteit Leuven (K.U.Leuven), Belgium. In 2000, she obtained her Ph.D. degree at the Rega Institute of the K.U.Leuven. After a postdoctoral stay at the New York University (NY, USA), she became a senior scientist at the Laboratory of Virology and Chemotherapy of the Rega Institute. Her research interests include the regulation of angiogenesis and apoptosis and how the balance between these processes affects tumor growth and metastasis.